• Jump to main navigation
  • Jump to content
U of U Health
  • Find A Doctor Find A U of U Health Doctor
  • Services All U of U Health Services
  • Locations All U of U Health Locations
  • For Patients & Visitors For All U of U Health Patients & Visitors
    • Patient Services
      • Questions About Your Bill?
      • Urgent Care
      • Where to Stay
      • Patients & Family Services
      • Clinical Trials
    • University of Utah Hospital
      • University of Utah Hospital
      • Staying at the Hospital
      • Parking & Valet
      • Looking for Another Location?
    • General Questions
      • 801-581-2668
      • Find an Interpreter
      • About U of U Health
  • Billing & Insurance
  • MyChart

Couriel, Daniel R., MD, MS

  • Clinical Information
  • Academic Information
  • Clinical Trials
  • Patient Resources
  • Videos & News
No Rating Available?
In order to provide our patients and visitors with the most accurate and useful information, we only post physician satisfaction data when a physician has received a minimum of 30 returned surveys. For this provider, we have not yet received the minimum.
34 4.9 out of 5 Patient Rating

Languages Spoken: English

Dr. Couriel received his M.D. degree in 1987 at the Universidad de Buenos Aires in Argentina. After fellowship training at Tufts University, NHLBI and Johns Hopkins University, he was appointed as Assistant Professor of Medicine at the University of Alabama Birmingham. In 1999 he moved to the M.D Anderson Cancer Center in the Department of Blood and Marrow Transplantation. He was promoted to Associate Professor in 2005, and in 2010 relocated to the Sarah Cannon Blood and Marrow Transplant Program in Nashville, TN where he was appointed as Director of the Allogeneic Transplant Program. In 2010 he moved to the University of Michigan Medical School where he served as Clinical Professor and Director of the Adult Blood and Marrow Transplantation Program. Dr. Couriel has a history of consistent funding and has more than 100 peer reviewed journal articles. His research interests are associated with new treatments and biomarkers for acute and chronic graft-versus-host disease. He serves on the Editorial Board of the Biology of Blood and Marrow Transplantation journal and in addition he co-chairs the GVHD subcommittee for the CIBMTR, and the Ancillary and Supportive Care committee of a NIH Consensus Project on Chronic GVHD.

Specialties

  • Hematology/BMT

Board Certification and Academic Information

Academic Departments Internal Medicine - Professor
Academic Divisions Hematology/BMT
Board Certification American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine (Sub: Medical Oncology)

Patient Rating

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Learn About Our Survey

Likelihood of recommending care provider

5.0/ 5

Care provider spoke using clear language

4.9/ 5

Care provider's explanation of condition/problem

5.0/ 5

My confidence in care provider

5.0/ 5

Care provider's effort to include me in decisions

4.9/ 5

Wait time at clinic

4.0/ 5

Time care provider spent with me

4.9/ 5

Care provider's concern for questions & worries

4.9/ 5

Care provider's friendliness and courtesy

5.0/ 5

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

UofU Patient
April 17, 2019
I appreciated the amount of time spent with myself and my wife as they discussed what was ahead of us and answering any questions we had.

UofU Patient
March 07, 2019
This is why I don't mind waiting a bit. Everyone I meet with is very knowledgeable, concerned, and friendly. They take the time to answer all my questions thoroughly.

UofU Patient
March 03, 2019
did not think care provider was well acquainted with my case

UofU Patient
January 15, 2019
Dr Couriel and Sam the PA are always very good.

UofU Patient
January 15, 2019
Dr. Couriel seemed very nice. this was a sort of one and done visit, since our main mission was to decide that for the moment I was fine and didn't need to come back. Was my fist meeting with him. I was previously treated by my beloved Dr. Zander.....So all went well, but we didn't have a whole lot to talk about. Good visit though.

UofU Patient
December 18, 2018
Dr. Couriel exemplifies the type of extremely knowledgeable, professional physician that supports what Huntsman is known for throughout the region.

UofU Patient
November 12, 2018
Very caring and understanding

UofU Patient
November 07, 2018
Sam and Dr Couriel are excellent. They listen, are very knowledgeable and very caring.

UofU Patient
November 02, 2018
everybody goes above and beyond to help and do what is necessary

UofU Patient
October 10, 2018
great doctor, very knowledgeable

UofU Patient
July 13, 2018
Dr. Couriel is a tremendous physician. His knowledge and expertise contribute to the high level of confidence that he brings to each interaction.

UofU Patient
May 25, 2018
Can't speak highly enough of Dr. Couriel and Sam.

UofU Patient
May 20, 2018
everyone at the Huntsman have been awesome!

UofU Patient
April 23, 2018
Dr Couriel always takes his time to explain things and he cares about each patient.

UofU Patient
April 04, 2018
Daniel Couriel brings a special meaning to patient care. From pre-transplant to 2 years post, he has always gone above and beyond in his care. If I could rate hire in the area of my confidence, I would. He is a fantastic physician.

UofU Patient
February 19, 2018
Always appreciate Dr. Couriel's attentiveness.

UofU Patient
February 17, 2018
Thankffulness!

UofU Patient
January 30, 2018
Dr. Couriel and Sam do an excellent job of explaining test results and my treatment path.

UofU Patient
January 30, 2018
Dr. Couriel has been fantastic throughout my transplant experience.

UofU Patient
January 25, 2018
Doctor Couriel is the best.

UofU Patient
January 16, 2018
fabulous

UofU Patient
December 03, 2017
Excellent care and understanding of my rare condition

UofU Patient
October 10, 2017
Afte the meeting with the team, I was greatly comforted with the process I would be undergoing for treatment. I was impressed with the organization of the team and their thoroughness and compassion.

UofU Patient
September 23, 2017
good

UofU Patient
June 26, 2017
The PA who helped me was very professional, personable, and clear in the explanations and advice that he gave me.

UofU Patient
April 15, 2017
All were fantastic...Ryan the PT, Dr. Couriel, the doctor working with him, and of course nurse Alma.

UofU Patient
March 26, 2017
The care has been excellent and all questions are answered so we understand them.

UofU Patient
January 29, 2017
Dr Couriel is a lifesaver. we are so blessed to have him as our doctor.

UofU Patient
October 19, 2016
Dr. Couriel is exceptional.

UofU Patient
September 01, 2016
Dr Couriel & Holly took a lot of time with me, explaining the past, present and future situation with my problem - including medications and treatment options.

UofU Patient
July 18, 2016
Dr. Couriel and Holly are excellent.

UofU Patient
April 21, 2016
my doctors, and especially the PAC Amanda were absolutely wonderful! I had a problem with scheduling for a pulmonary test, as I showed up when told got clear over there with transport and they wouldn't do the test because it was 5:00 pm and they didn't work after 5:00pm. they should not have scheduled me then!

UofU Patient
March 29, 2016
Everyone was super kind, understanding and caring. Love the staff at Huntsman.

UofU Patient
January 07, 2016
Always thorough and check out everything. We trust them and feel they have our best interest in mind.

Dr. Couriel received his M.D. degree in 1987 at the Universidad de Buenos Aires in Argentina. After fellowship training at Tufts University, NHLBI and Johns Hopkins University, he was appointed as Assistant Professor of Medicine at the University of Alabama Birmingham. In 1999 he moved to the M.D Anderson Cancer Center in the Department of Blood and Marrow Transplantation. He was promoted to Associate Professor in 2005, and in 2010 relocated to the Sarah Cannon Blood and Marrow Transplant Program in Nashville, TN where he was appointed as Director of the Allogeneic Transplant Program. In 2010 he moved to the University of Michigan Medical School where he served as Clinical Professor and Director of the Adult Blood and Marrow Transplantation Program. Dr. Couriel has a history of consistent funding and has more than 100 peer reviewed journal articles. His research interests are associated with new treatments and biomarkers for acute and chronic graft-versus-host disease. He serves on the Editorial Board of the Biology of Blood and Marrow Transplantation journal and in addition he co-chairs the GVHD subcommittee for the CIBMTR, and the Ancillary and Supportive Care committee of a NIH Consensus Project on Chronic GVHD.

Academic Locations

Huntsman Cancer Institute

801-585-2626

2000 Circle of Hope
University of Utah Hospital, Hematology, 2151
Salt Lake City, UT  84112

Board Certification and Academic Information

Academic Departments Internal Medicine - Professor
Academic Divisions Hematology/BMT
Board Certification American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine (Sub: Medical Oncology)

Research Interests

  • New Treatments for Acute Graft-Versus Host Disease
  • Biomarkers and New Treatments for Chronic Graft-Versus Host Disease
  • Ancillary and Supportive Care for Chronic Graft-Versus-Host Disease
  • Long Term Complications and Survivorship Issues after Allogeneic Stem Cell Transplantation
  • Multidisciplinary Interventions and Patient Reported Outcomes in the Assessment of Response to Therapy in Chronic Graft-Versus Host Disease

Education History

Residency George Washington University Hospital
Internal Medicine
Resident
Fellowship National Heart, Lung, and Blood Institute
Hematology
Fellow
Fellowship Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Bone Marrow Transplantation Unit
Fellow
Fellowship Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Leukemia Unit
Fellow
Fellowship St. Elizabeth’s Medical Center, Tufts University School of Medicine
Hematology/Oncology
Fellow
Residency University of Buenos Aires
Internal Medicine
Resident
Professional Medical University of Buenos Aires School of Medicine
Medicine
M.D.

Selected Publications - Journal Articles

Journal Article

  1. Nikiforow S, Wang T, Hemmer M, Spellman S, Akpek G, Antin JH, Choi SW, Inamoto Y, Khoury HJ, MacMillan M, Marks DI, Meehan K, Nakasone H, Nishihori T, Olsson R, Paczesny S, Przepiorka D, Reddy V, Reshef R, Schoemans H, Waller N, Weisdorf D, Wirk B, Horowitz M, Alousi A, Couriel D, Pidala J, Arora M, Cutler C (2018 Oct). Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated. Haematologica, 103(10), 1708-1719.
  2. Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Yingst A, Couriel D, Alousi A, Pidala J, Knight JM, Verneris MR (2018 Aug 23). Proinflammatory Cytokine and Adipokine Levels in Adult Unrelated Marrow Donors Are Not Associated with Hematopoietic Cell Transplantation Outcomes.LID - S1083-8791(18)30476-2 [pii]LID - 10.1016/j.bbmt.2018.08.011 [doi]. (Epub ahead of print) Biol Blood Marrow Transplant.
  3. Kumar AJ, Kim S, Hemmer MT, Arora M, Spellman SR, Pidala JA, Couriel DR, Alousi AM, Aljurf MD, Cahn JY, Cairo MS, Cutler CS, Farhan S, Gergis U, Hale GA, Hashmi SK, Inamoto Y, Kamble RT, Kharfan-Dabaja MA, MacMillan ML, Marks DI, Nakasone H, Norkin M, Qayed M, Ringden O, Schouten HC, Schultz KR, Solh MM, Teshima T, Urbano-Ispizua A, Verdonck LF, Gale RP, Hamilton BK, Majhail NS, Loren AW (2018 May 8). Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. Blood Adv, 2(9), 1022-1031.
  4. Radojcic V, Lee CJ, Couriel DR (2018 Sep). Multifaceted Burden of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant, 24(9), 1774-1775.
  5. Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin JH, Verdonck LF, Lehmann L, Aljurf MD, MacMillan ML, Litzow MR, Solh MM, Qayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK (2018 Aug 25). Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.LID - S1083-8791(18)30489-0 [pii]LID - 10.1016/j.bbmt.2018.08.018 [doi]. (Epub ahead of print) Biol Blood Marrow Transplant.
  6. Alousi A, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Pidala J, Anderlini PN, Boyiadzis M, Bredeson CN, Cahn JY, Cairo MS, Gadalla SM, Hashmi SK, Gale RP, Kanda J, Kamble RT, Kharfan-Dabaja MA, Litzow MR, Ringden O, Saad AA, Schultz KR, Verdonck LF, Waller EK, Yared JA, Holtan SG, Weisdorf DJ (2018 Oct 3). Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow allografts have improved Long-term Overall and Graft-versus-Host Disease, Relapse-Free Survival.LID - S1083-8791(18)30561-5 [pii]LID - 10.1016/j.bbmt.2018.09.004 [doi]. (Epub ahead of print) Biol Blood Marrow Transplant.
  7. Qayed M, Wang T, Hemmer MT, Spellman S, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Aljurf M, Ayas M, Bitan M, Cairo M, Choi SW, Dandoy C, Delgado D, Gale RP, Hale G, Frangoul H, Kamble RT, Kharfan-Dabaja M, Lehman L, Levine J, MacMillan M, Marks DI, Nishihori T, Olsson RF, Hematti P, Ringden O, Saad A, Satwani P, Savani BN, Schultz KR, Seo S, Shenoy S, Waller EK, Yu L, Horowitz MM, Horan J (2018 Mar). Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. Biol Blood Marrow Transplant, 24(3), 521-528.
  8. Miller HK, Braun TM, Stillwell T, Harris AC, Choi S, Connelly J, Couriel D, Goldstein S, Kitko CL, Magenau J, Pawarode A, Reddy P, Riwes M, Yanik GA, Levine JE (2017 Mar). Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant, 23(3), 522-528.
  9. Khoury HJ, Wang T, Hemmer MT, Couriel D, Alousi A, Cutler C, Aljurf M, Antin JH, Ayas M, Battiwalla M, Cahn JY, Cairo M, Chen YB, Gale RP, Hashmi S, Hayashi RJ, Jagasia M, Juckett M, Kamble RT, Kharfan-Dabaja M, Litzow M, Majhail N, Miller A, Nishihori T, Qayed M, Schoemans H, Schouten HC, Socie G, Storek J, Verdonck L, Vij R, Wood WA, Yu L, Martino R, Carabasi M, Dandoy C, Gergis U, Hematti P, Solh M, Jamani K, Lehmann L, Savani B, Schultz KR, Wirk BM, Spellman S, Arora M, Pidala J (2017 May). Improved survival after acute graft-versus-host disease diagnosis in the modern era. Haematologica, 102(5), 958-966.
  10. Krakow EF, Hemmer M, Wang T, Logan B, Arora M, Spellman S, Couriel D, Alousi A, Pidala J, Last M, Lachance S, Moodie EEM (2017 Jul 15). Tools for the Precision Medicine Era: How to Develop Highly Personalized Treatment Recommendations From Cohort and Registry Data Using Q-Learning. Am J Epidemiol, 186(2), 160-172.
  11. Saliba RM, Sarantopoulos S, Kitko CL, Pawarode A, Goldstein SC, Magenau J, Alousi AM, Churay T, Justman H, Paczesny S, Reddy P, Couriel DR (2017 Jul). B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality. Bone Marrow Transplant, 52(7), 1010-1015.
  12. Votruba KL, Hoodin F, Giordani B, Kentor R, Couriel DR, Kitko CL (2017 Aug). Prospective computerized monitoring of cognitive functioning before and after blood and marrow transplantation. Bone Marrow Transplant, 52(8), 1215-1217.
  13. Miceli MH, Churay T, Braun T, Kauffman CA, Couriel DR (2017 Jan 25). Risk Factors and Outcomes of Invasive Fungal Infections in Allogeneic Hematopoietic Cell Transplant Recipients.LID - 10.1007/s11046-017-0115-y [doi]. (Epub ahead of print) Mycopathologia.
  14. Chen YB, Wang T, Hemmer MT, Brady C, Couriel DR, Alousi A, Pidala J, Urbano-Ispizua A, Choi SW, Nishihori T, Teshima T, Inamoto Y, Wirk B, Marks DI, Abdel-Azim H, Lehmann L, Yu L, Bitan M, Cairo MS, Qayed M, Salit R, Gale RP, Martino R, Jaglowski S, Bajel A, Savani B, Frangoul H, Lewis ID, Storek J, Askar M, Kharfan-Dabaja MA, Aljurf M, Ringden O, Reshef R, Olsson RF, Hashmi S, Seo S, Spitzer TR, MacMillan ML, Lazaryan A, Spellman SR, Arora M, Cutler CS (2016 Dec 12). GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes.LID - 10.1038/bmt.2016.265 [doi]. (Epub ahead of print) Bone Marrow Transplant.
  15. Song Y, Magenau J, Li Y, Braun T, Chang L, Bixby D, Hanauer DA, Chughtai KA, Gatza E, Couriel D, Goldstein S, Pawarode A, Reddy P, Riwes M, Connelly J, Harris A, Kitko C, Levine J, Yanik G, Parkin B, Choi SW (2016 Apr). FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. Bone Marrow Transplant, 51(4), 511-520.
  16. Kitko CL, Braun T, Couriel DR, Choi SW, Connelly J, Hoffmann S, Goldstein S, Magenau J, Pawarode A, Reddy P, Schuler C, Yanik GA, Ferrara JL, Levine JE (2016 May). Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial. Biol Blood Marrow Transplant, 22(5), 862-8.
  17. Pawarode A, Mineishi S, Reddy P, Braun TM, Khaled YA, Choi SW, Magenau JM, Harris AC, Connelly JA, Kitko CL, Parkin BL, Goldstein SC, Yanik GA, Levine JE, Ferrara JL, Couriel DR (2016). Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series. Biol Blood Marrow Transplant, 22(1), 54-60.
  18. Eissenberg LG, Rettig MP, Ritchey JK, Prior JL, Schwarz SW, Frye J, White BS, Fulton RS, Ghobadi A, Cooper ML, Couriel DR, Seegulam ME, Piwnica-Worms D, Dehdashti F, Cornetta K, DiPersio JF (2015 Jun). [18F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T Cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility. Mol Ther, 23(6), 1110-1122.
  19. Inamoto Y, Flowers ME, Wang T, Urbano-Ispizua A, Hemmer MT, Cutler CS, Couriel DR, Alousi AM, Antin JH, Gale RP, Gupta V, Hamilton BK, Kharfan-Dabaja MA, Marks DI, Ringden OT, Socie G, Solh MM, Akpek G, Cairo MS, Chao NJ, Hayashi RJ, Nishihori T, Reshef R, Saad A, Shah A, Teshima T, Tallman MS, Wirk B, Spellman SR, Arora M, Martin PJ (2015 Oct). Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. Biol Blood Marrow Transplant, 21(10), 1776-82.
  20. Zhu L, Couriel DR, Chang CH (2015 Jul 18). The effect of extracorporeal photopheresis on T cell response in chronic graft-versus-host disease. Leuk Lymphoma, 1-9.
  21. Miceli MH, Perissinotti AJ, Kauffman CA, Couriel DR (2015 Jul). Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis. Mycoses, 58(7), 432-6.
  22. Zhou C, Chan HP, Dong Q, Couriel DR, Pawarode A, Hadjiiski LM, Wei J (2015 Jul 20). Quantitative Analysis of MR Imaging to Assess Treatment Response for Patients with Multiple Myeloma by Using Dynamic Intensity Entropy Transformation: A Preliminary Study. Radiology, 142804.
  23. Eapen M, Logan BR, Appelbaum FR, Antin JH, Anasetti C, Couriel DR, Chen J, Maziarz RT, McCarthy PL, Nakamura R, Ratanatharathorn V, Vij R, Champlin RE (2015 Jan). Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. Biol Blood Marrow Transplant, 21(1), 55-9.
  24. Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Bacigalupo AA, Battiwalla M, Flowers ME, Juckett MB, Lee SJ, Loren AW, Klumpp TR, Prockup SE, Ringden OT, Savani BN, Socie G, Schultz KR, Spitzer T, Teshima T, Bredeson CN, Jacobsohn DA, Hayashi RJ, Drobyski WR, Frangoul HA, Akpek G, Ho VT, Lewis VA, Gale RP, Koreth J, Chao NJ, Aljurf MD, Cooper BW, Laughlin MJ, Hsu JW, Hematti P, Verdonck LF, Solh MM, Norkin M, Reddy V, Martino R, Gadalla S, Goldberg JD, McCarthy PL, Perez-Simon JA, Khera N, Lewis ID, Atsuta Y, Olsson RF, Saber W, Waller EK, Blaise D, Pidala JA, Martin PJ, Satwani P, Bornhauser M, Inamoto Y, Weisdorf DJ, Horowitz MM, Pavletic SZ (2015 Feb). Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant, 21(2), 266-74.
  25. Ratcliffe N, Dunbar NM, Adamski J, Couriel D, Edelson R, Kitko CL, Levine JE, Morgan S, Schneiderman J, Sloan S, Wu Y, Szczepiorkowski ZM, Cooling L (2015 Jan). National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: scientific opportunities in extracorporeal photopheresis. Transfus Med Rev, 29(1), 62-70.
  26. Arora M, Hemmer MT, Ahn KW, Klein JP, Cutler CS, Urbano-Ispizua A, Couriel DR, Alousi AM, Gale RP, Inamoto Y, Weisdorf DJ, Li P, Antin JH, Bolwell BJ, Boyiadzis M, Cahn JY, Cairo MS, Isola LM, Jacobsohn DA, Jagasia M, Klumpp TR, Petersdorf EW, Santarone S, Schouten HC, Wingard JR, Spellman SR, Pavletic SZ, Lee SJ, Horowitz MM, Flowers ME (2015 Apr). Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort. Biol Blood Marrow Transplant, 21(4), 640-5.
  27. Abedin S, Yanik GA, Braun T, Pawarode A, Magenau J, Goldstein SC, Levine JE, Kitko CL, Couriel DR (2015 Jun). Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung. Biol Blood Marrow Transplant, 21(6), 1127-31.
  28. Caram MV, Bellile EL, Englesbe MJ, Terjimanian M, Wang SC, Griggs JJ, Couriel D (2015 Jun 18). Sarcopenia is associated with autologous transplant-related outcomes in patients with lymphoma. Leuk Lymphoma, 1-8.
  29. Magenau JM, Braun T, Reddy P, Parkin B, Pawarode A, Mineishi S, Choi S, Levine J, Li Y, Yanik G, Kitko C, Churay T, Frame D, Riwes MM, Harris A, Bixby D, Couriel DR, Goldstein SC (2015 Jun). Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission. Ann Hematol, 94(6), 1033-41.
  30. Eissenberg LG, Rettig MP, Ritchey JK, Prior JL, Schwarz SW, Frye J, White BS, Fulton RS, Ghobadi A, Cooper ML, Couriel DR, Seegulam ME, Piwnica-Worms D, Dehdashti F, Cornetta K, DiPersio JF (2015 Jun). [(18)F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T Cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility. Mol Ther, 23(6), 1110-22.
  31. Choi SW, Braun T, Chang L, Ferrara JL, Pawarode A, Magenau JM, Hou G, Beumer JH, Levine JE, Goldstein S, Couriel DR, Stockerl-Goldstein K, Krijanovski OI, Kitko C, Yanik GA, Lehmann MH, Tawara I, Sun Y, Paczesny S, Mapara MY, Dinarello CA, DiPersio JF, Reddy P (2014 Jan). Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol, 15(1), 87-95.
  32. Kitko CL, Levine JE, Storer BE, Chai X, Fox DA, Braun TM, Couriel DR, Martin PJ, Flowers ME, Hansen JA, Chang L, Conlon M, Fiema BJ, Morgan R, Pongtornpipat P, Lamiman K, Ferrara JL, Lee SJ, Paczesny S (2014 Jan 30). Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. Blood, 123(5), 786-93.
  33. Gatza E, Braun T, Levine JE, Ferrara JL, Zhao S, Wang T, Chang L, Harris A, Pawarode A, Kitko C, Magenau JM, Yanik GA, Couriel DR, Goldstein S, Connelly J, Reddy P, Paczesny S, Choi SW (2014 Sep). Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant, 20(9), 1426-34.
  34. Galban CJ, Boes JL, Bule M, Kitko CL, Couriel DR, Johnson TD, Lama V, Telenga ED, van den Berge M, Rehemtulla A, Kazerooni EA, Ponkowski MJ, Ross BD, Yanik GA (2014 Oct). Parametric response mapping as an indicator of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 20(10), 1592-8.
  35. Abedin S, Peres E, Levine JE, Choi S, Yanik G, Couriel DR (2014 Dec). Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation. Biol Blood Marrow Transplant, 20(12), 2062-6.
  36. Harris AC, Kitko CL, Couriel DR, Braun TM, Choi SW, Magenau J, Mineishi S, Pawarode A, Yanik G, Levine JE (2013 Feb). Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Haematologica, 98(2), 179-84.
  37. Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, Zhang Q, Wong CH, Wang H, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel D, Reddy P, Ferrara JL, Paczesny S (2013 Aug 8). ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med, 369(6), 529-39.
  38. Saliba RM, Couriel DR, Giralt S, Rondon G, Okoroji GJ, Rashid A, Champlin RE, Alousi AM (2012 Jan). Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant, 47(1), 125-31.
  39. Ciurea SO, Saliba RM, Hamerschlak N, Karduss Aurueta AJ, Bassett R, Fernandez-Vina M, Petropoulos D, Worth LL, Chan KW, Couriel DR, Rondon G, Sharma M, Qazilbash M, Jones RB, Kebriaei P, McMannis J, Hosing CM, Nieto Y, Champlin RE, Shpall EJ, de Lima M (2012 May). Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. Leuk Lymphoma, 53(5), 901-6.
  40. Bashir Q, Munsell MF, Giralt S, de Padua Silva L, Sharma M, Couriel D, Chiattone A, Popat U, Qazilbash MH, Fernandez-Vina M, Champlin RE, de Lima MJ (2012 May). Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant. Leuk Lymphoma, 53(5), 915-9.
  41. Blazar B, White ES, Couriel D (2012 Jan). Understanding chronic GVHD from different angles. Biol Blood Marrow Transplant, 18(1 Suppl), S184-8.
  42. Harris AC, Ferrara JL, Braun TM, Holler E, Teshima T, Levine JE, Choi SW, Landfried K, Akashi K, Vander Lugt M, Couriel DR, Reddy P, Paczesny S (2012 Mar 22). Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood, 119(12), 2960-3.
  43. Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Nordgren B, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R (2012 Aug 30). A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood, 120(9), 1801-9.
  44. Martin PJ, Storer BE, Carpenter PA, Couriel DR, Flowers ME, Gupta V, Hsu JW, Jagasia M, Kitko CL, Maziarz RT, Rowley SD, Shaughnessy PJ, van Besien K, Weisdorf D, Lee SJ (2011 Jan). Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant, 17(1), 124-32.
  45. Parmar S, Andersson BS, Couriel D, Munsell MF, Fernandez-Vina M, Jones RB, Shpall EJ, Popat U, Anderlini P, Giralt S, Alousi A, Cano P, Bosque D, Hosing C, Silva Lde P, Westmoreland M, Wathen JK, Berry D, Champlin RE, de Lima MJ (2011 Jan 20). Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. J Clin Oncol, 29(3), 294-302.
  46. Joseph RW, Alousi A, Konda B, Komanduri K, Neumann J, Trevino C, Stolar K, Qazilbash M, Hosing C, Kebriaei P, Couriel DR, Champlin RE, Saliba R, Popat U (2011 Nov). High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. Am J Hematol, 86(11), 954-6.
  47. Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Anderlini P, Rondon G, Andersson BS, Champlin R, Couriel DR (2011). Steroid-Refractory Acute GVHD: Predictors and Outcomes. Adv Hematol, 2011, 601953.
  48. Saliba RM, Komanduri KV, Giralt S, de Souza J, Patah P, Oran B, Couriel D, Rondon G, Champlin RE, de Lima M (2009 May). Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. Bone Marrow Transplant, 43(9), 685-92.
  49. Wang Y, Li D, Jones D, Bassett R, Sale GE, Khalili J, Komanduri KV, Couriel DR, Champlin RE, Molldrem JJ, Ma Q (2009 Dec). Blocking LFA-1 activation with lovastatin prevents graft-versus-host disease in mouse bone marrow transplantation. Biol Blood Marrow Transplant, 15(12), 1513-22.
  50. Couriel DR, Saliba R, de Lima M, Giralt S, Andersson B, Khouri I, Hosing C, Ippoliti C, Shpall EJ, Champlin R, Alousi A (2009 Dec). A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant, 15(12), 1555-62.
  51. Cheng YC, Rondon G, Sanchez LF, McMannis JD, Couriel DR, de Lima MJ, Hosing C, Khouri IF, Giralt SA, Champlin RE, Ueno NT (2009 Dec). Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Int J Hematol, 90(5), 627-34.
  52. Bashoura L, Gupta S, Jain A, Couriel DR, Komanduri KV, Eapen GA, Safdar A, Broglio KR, Adachi R, Dickey BF (2008 Jan). Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation. Bone Marrow Transplant, 41(1), 63-7.
  53. de Lima M, Champlin RE, Thall PF, Wang X, Martin TG 3rd, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S (2008 Feb). Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia, 22(2), 258-64.
  54. Ross WA, Ghosh S, Dekovich AA, Liu S, Ayers GD, Cleary KR, Lee JH, Couriel D (2008 Apr). Endoscopic biopsy diagnosis of acute gastrointestinal graft-versus-host disease: rectosigmoid biopsies are more sensitive than upper gastrointestinal biopsies. Am J Gastroenterol, 103(4), 982-9.
  55. de Lima M, McMannis J, Gee A, Komanduri K, Couriel D, Andersson BS, Hosing C, Khouri I, Jones R, Champlin R, Karandish S, Sadeghi T, Peled T, Grynspan F, Daniely Y, Nagler A, Shpall EJ (2008 May). Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant, 41(9), 771-8.
  56. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell MF, Champlin RE (2008 Feb). Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica, 93(2), 257-64.
  57. Hosing C, Saliba RM, Okoroji GJ, Popat U, Couriel D, Ali T, De Padua Silva L, Kebriaei P, Alousi A, De Lima M, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I (2008 Jun). High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. Ann Oncol, 19(6), 1166-71.
  58. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE (2008 Jun 15). Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood, 111(12), 5530-6.
  59. Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, Shpall EJ, Jones RB, Champlin RE (2008 Jun). Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant, 14(6), 672-84.
  60. Macmillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming TR, Huang S, Roskos L, Slavin S, Shadduck RK, Dipersio J, Territo M, Pavletic S, Linker C, Heslop HE, Deeg HJ, Blazar BR (2007 Mar 15). A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood, 109(6), 2657-62.
  61. Saliba RM, de Lima M, Giralt S, Andersson B, Khouri IF, Hosing C, Ghosh S, Neumann J, Hsu Y, De Jesus J, Qazilbash MH, Champlin RE, Couriel DR (2007 Apr 1). Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood, 109(7), 2751-8.
  62. Madden T, de Lima M, Thapar N, Nguyen J, Roberson S, Couriel D, Pierre B, Shpall EJ, Jones RB, Champlin RE, Andersson BS (2007 Jan). Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant, 13(1), 56-64.
  63. Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA (2007 Mar). Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant, 39(5), 279-83.
  64. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, Couriel D, Qazilbash M, Anderlini P, Kebriaei P, Ghosh S, Carrasco-Yalan A, de Meis E, Anagnostopoulos A, Donato M, Champlin RE, de Lima M (2007 Apr). Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant, 13(4), 454-62.
  65. Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, Shpall EJ, Qazilbash MH, Molldrem JJ, Chemaly RF, Komanduri KV (2007 Jul). Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant, 40(2), 125-36.
  66. Jabbour E, Rondon G, Anderlini P, Giralt SA, Couriel DR, Champlin RE, Khouri IF (2007 Sep). Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant, 40(5), 431-5.
  67. Kebriaei P, Detry MA, Giralt S, Carrasco-Yalan A, Anagnostopoulos A, Couriel D, Khouri IF, Anderlini P, Hosing C, Alousi A, Champlin RE, de Lima M (2007 Nov 1). Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood, 110(9), 3456-62.
  68. Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA (2007 Sep). Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant, 13(9), 1066-72.
  69. Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, Smith V, Khouri I, Giralt S, de Lima M, Hsu Y, Ghosh S, Neumann J, Andersson B, Qazilbash M, Hymes S, Kim S, Champlin R, Donato M (2006 Apr 15). Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood, 107(8), 3074-80.
  70. Couriel D, Hosing C, Saliba R, Shpall EJ, Andelini P, Popat U, Donato M, Champlin R (2006 Jan). Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work? Biol Blood Marrow Transplant, 12(1 Suppl 2), 37-40.
  71. Qazilbash MH, Saliba R, De Lima M, Hosing C, Couriel D, Aleman A, Roden L, Champlin R, Giralt SA (2006 Mar 1). Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer, 106(5), 1084-9.
  72. Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, Turner ML, Akpek G, Gilman A, McDonald G, Schubert M, Berger A, Bross P, Chien JW, Couriel D, Dunn JP, Fall-Dickson J, Farrell A, Flowers ME, Greinix H, Hirschfeld S, Gerber L, Kim S, Knobler R, Lachenbruch PA, Miller FW, Mittleman B, Papadopoulos E, Parsons SK, Przepiorka D, Robinson M, Ward M, Reeve B, Rider LG, Shulman H, Schultz KR, Weisdorf D, Vogelsang GB (2006 Mar). Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant, 12(3), 252-66.
  73. Kebriaei P, Saliba RM, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S, Qazilbash MH, Gajewski JL, Ha CS, Champlin RE, Khouri IF (2006 Aug). Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant, 38(3), 203-9.
  74. Lee HJ, Oran B, Saliba RM, Couriel DM, Shin K, Massey P, Neumann J, de Lima M, Champlin R, Giralt S (2006 Aug). Steroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapy. Bone Marrow Transplant, 38(4), 299-303.
  75. Lekakis L, Giralt S, Couriel D, Shpall EJ, Hosing C, Khouri IF, Anderlini P, Korbling M, Martin T, Champlin RE, de Lima M (2006 Sep). Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant, 38(6), 421-6.
  76. Hosing C, Saliba RM, Korbling M, Acholonu S, McMannis J, Anderlini P, Giralt S, De Lima M, Okoroji GJ, Couriel DR, Champlin R, Khouri IF, Donato ML (2006 Jul). High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma, 47(7), 1290-4.
  77. Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, Gajewski J, Alamo J, Couriel D, Andersson BS, Donato M, Hosing C, Komanduri K, Anderlini P, Molldrem J, Ueno NT, Estey E, Ippoliti C, Champlin R, Giralt S (2005 Feb). Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant, 11(2), 108-14.
  78. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, Couriel D, De Lima M, Donato ML, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning JT, Pro B, Shpall E, Younes A, McLaughlin P, Champlin RE (2005 Apr 1). Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol, 23(10), 2240-7.
  79. Hosing C, Saliba RM, Shahjahan M, Estey EH, Couriel D, Giralt S, Andersson B, Champlin RE, De Lima M (2005 Jul). Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant, 36(2), 157-62.
  80. Couriel DR, Saliba R, Escalon MP, Hsu Y, Ghosh S, Ippoliti C, Hicks K, Donato M, Giralt S, Khouri IF, Hosing C, de Lima MJ, Andersson B, Neumann J, Champlin R (2005 Aug). Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol, 130(3), 409-17.
  81. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME (2005 Dec). National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant, 11(12), 945-56.
  82. Stanzani M, Martins SL, Saliba RM, St John LS, Bryan S, Couriel D, McMannis J, Champlin RE, Molldrem JJ, Komanduri KV (2004 Feb 1). CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans. Blood, 103(3), 1140-6.
  83. Khouri IF, Lee MS, Saliba RM, Andersson B, Anderlini P, Couriel D, Hosing C, Giralt S, Korbling M, McMannis J, Keating MJ, Champlin RE (2004 Jan). Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol, 32(1), 28-35.
  84. El-Zimaity M, Saliba R, Chan K, Shahjahan M, Carrasco A, Khorshid O, Caldera H, Couriel D, Giralt S, Khouri I, Ippoliti C, Champlin R, de Lima M (2004 Jun 15). Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters. Blood, 103(12), 4674-80.
  85. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M, Hosing C, Anderlini P, Donato M, Cleary K, Gajewski J, Neumann J, Ippoliti C, Rondon G, Cohen A, Champlin R (2004 Mar). Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant, 10(3), 178-85.
  86. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin R (2004 Aug 1). Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood, 104(3), 649-54.
  87. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, Shpall EJ, Shahjahan M, Pierre B, Giralt S, Korbling M, Russell JA, Champlin RE, Andersson BS (2004 Aug 1). Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood, 104(3), 857-64.
  88. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin R, Giralt S (2004 Aug 1). Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood, 104(3), 865-72.
  89. Anderlini P, Acholonu SA, Okoroji GJ, Andersson BS, Couriel DR, De Lima MJ, Donato ML, Khouri IF, Giralt SA, Ueno NT, Champlin RE (2004 Sep). Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. Bone Marrow Transplant, 34(6), 511-4.
  90. de Lima M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, Khouri I, Gajewski J, van Besien K, Champlin R, Giralt S, Kantarjian H (2003 Mar 1). Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer, 97(5), 1242-7.
  91. Apisarnthanarax N, Donato M, Korbling M, Couriel D, Gajewski J, Giralt S, Khouri I, Hosing C, Champlin R, Duvic M, Anderlini P (2003 Mar). Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant, 31(6), 459-65.
  92. Wong R, Beguelin GZ, de Lima M, Giralt SA, Hosing C, Ippoliti C, Forman AD, Kumar AJ, Champlin R, Couriel D (2003 Jul). Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol, 122(1), 128-34.
  93. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C, Andersson BS, Cano P, Shahjahan M, Ippoliti C, Estey EH, McMannis J, Gajewski JL, Champlin RE, de Lima M (2003 Oct 15). Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood, 102(8), 3052-9.
  94. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE (2003 Nov 15). Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood, 102(10), 3829-36.
  95. Lee SJ, Vogelsang G, Gilman A, Weisdorf DJ, Pavletic S, Antin JH, Horowitz MM, Akpek G, Flowers ME, Couriel D, Martin PJ (2002). A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant, 8(1), 32-9.
  96. Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M, Donato M, Gajewski J, Giralt S, Korbling M, Martin T, Ueno NT, Champlin RE, Khouri IF (2002 Mar). Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol, 13(3), 450-9.
  97. Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, Anderlini P, de Lima M, Gajewski J, Champlin RE (2002). Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant, 8(9), 477-85.
  98. De Lima M, St John LS, Wieder ED, Lee MS, McMannis J, Karandish S, Giralt S, Beran M, Couriel D, Korbling M, Bibawi S, Champlin R, Komanduri KV (2002 Dec). Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units. Br J Haematol, 119(3), 773-6.
  99. Rodriguez J, Munsell M, Yazji S, Hagemeister FB, Younes A, Andersson B, Giralt S, Gajewski J, de Lima M, Couriel D, Romaguera J, Cabanillas FF, Champlin RE, Khouri IF (2001 Sep 1). Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol, 19(17), 3766-70.
  100. Lewalle P, Hensel N, Guimaraes A, Couriel D, Jiang Y Z, Mavroudis D, Barrett AJ (1996 Mar). Helper and cytotoxic lymphocyte responses to chronic myeloid leukaemia: implications for adoptive immunotherapy with T cells. Br J Haematol, 92(3), 587-94.
  101. Jiang YZ, Couriel D, Mavroudis DA, Lewalle P, Malkovska V, Hensel NF, Dermime S, Molldrem J, Barrett AJ (1996 Mar). Interaction of natural killer cells with MHC class II: reversal of HLA-DR1-mediated protection of K562 transfectant from natural killer cell-mediated cytolysis by brefeldin-A. Immunology, 87(3), 481-6.
  102. Mavroudis DA, Jiang YZ, Hensel N, Lewalle P, Couriel D, Kreitman RJ, Pastan I, Barrett AJ (1996 May). Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. Bone Marrow Transplant, 17(5), 793-9.
  103. Jiang YZ, Mavroudis D, Dermime S, Hensel N, Couriel D, Molldrem J, Barrett AJ (1996 Jun). Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. Br J Haematol, 93(3), 606-12.
  104. Couriel D, Canosa J, Engler H, Collins A, Dunbar C, Barrett AJ (1996 Aug). Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies. Bone Marrow Transplant, 18(2), 347-53.
  105. Mavroudis D, Read E, Cottler-Fox M, Couriel D, Molldrem J, Carter C, Yu M, Dunbar C, Barrett J (1996 Oct 15). CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood, 88(8), 3223-9.
  106. Couriel D, Weinstein R (1994). Complications of therapeutic plasma exchange: a recent assessment. J Clin Apheresis, 9(1), 1-5.

Review

  1. MacDonald KPA, Betts BC, Couriel D (2018 Jan). Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease. [Review]. Biol Blood Marrow Transplant, 24(1), 19-26.
  2. MacDonald KPA, Betts BC, Couriel D (2018 Mar). Reprint of: Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease. [Review]. Biol Blood Marrow Transplant, 24(3S), S7-S14.
  3. Couriel DR, Ricker H, Steinbach M, Lee CJ (2016 Aug). Neurologic Manifestations of Blood Dyscrasias. [Review]. Hematol Oncol Clin North Am, 30(4), 723-31.
  4. Syed FI, Couriel DR, Frame D, Srinivasan A (2016 Aug). Central Nervous System Complications of Hematopoietic Stem Cell Transplant. [Review]. Hematol Oncol Clin North Am, 30(4), 887-98.
  5. Smith SR, Haig AJ, Couriel DR (2015 May). Musculoskeletal, Neurologic, and Cardiopulmonary Aspects of Physical Rehabilitation in Patients with Chronic Graft-versus-Host Disease. [Review]. Biol Blood Marrow Transplant, 21(5), 799-808.
  6. Radojcic V, Pletneva MA, Couriel DR (2015 Apr). The role of extracorporeal photopheresis in chronic graft-versus-host disease. [Review]. Transfus Apheresis Sci, 52(2), 157-61.
  7. Magenau J, Couriel DR (2013 Oct). Hematopoietic stem cell transplantation for acute myeloid leukemia: to whom, when, and how. [Review]. Curr Oncol Rep, 15(5), 436-44.
  8. Fortune K, Couriel D (2009 Jul). Tacrolimus in hematopoietic stem cell transplantation. [Review]. Expet Opin Drug Metabol Toxicol, 5(7), 835-41.
  9. Knobler R, Barr ML, Couriel DR, Ferrara JL, French LE, Jaksch P, Reinisch W, Rook AH, Schwarz T, Greinix H (2009 Oct). Extracorporeal photopheresis: past, present, and future. [Review]. J Am Acad Dermatol, 61(4), 652-65.
  10. Couriel DR (2008 Jun). Ancillary and supportive care in chronic graft-versus-host disease. [Review]. Baillieres Best Pract Res Clin Haematol, 21(2), 291-307.
  11. Joseph RW, Couriel DR, Komanduri KV (2008 Nov-Dec). Chronic graft-versus-host disease after allogeneic stem cell transplantation: challenges in prevention, science, and supportive care. [Review]. J Support Oncol, 6(8), 361-72.
  12. Shlomchik WD, Lee SJ, Couriel D, Pavletic SZ (2007 Jan). Transplantation's greatest challenges: advances in chronic graft-versus-host disease. [Review]. Biol Blood Marrow Transplant, 13(1 Suppl 1), 2-10.
  13. Komanduri KV, Couriel D, Champlin RE (2006 Jan). Graft-versus-host disease after allogeneic stem cell transplantation: evolving concepts and novel therapies including photopheresis. [Review]. Biol Blood Marrow Transplant, 12(1 Suppl 2), 1-6.
  14. Hymes SR, Turner ML, Champlin RE, Couriel DR (2006 Nov). Cutaneous manifestations of chronic graft-versus-host disease. [Review]. Biol Blood Marrow Transplant, 12(11), 1101-13.
  15. Ross WA, Couriel D (2005 Jan). Colonic graft-versus-host disease. [Review]. Curr Opin Gastroenterol, 21(1), 64-9.
  16. Couriel D, Caldera H, Champlin R, Komanduri K (2004 Nov 1). Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. [Review]. Cancer, 101(9), 1936-46.
  17. Antin JH, Chen AR, Couriel DR, Ho VT, Nash RA, Weisdorf D (2004 Oct). Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. [Review]. Biol Blood Marrow Transplant, 10(10), 655-68.
  18. Couriel DR, Beguelin GZ, Giralt S, De Lima M, Hosing C, Kharfan-Dabaja MA, Anagnostopoulos A, Champlin R (2002 Oct). Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation. [Review]. Bone Marrow Transplant, 30(8), 543-6.
  19. Couriel DR, Hicks K, Giralt S, Champlin RE (2000 Nov). Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation. [Review]. Curr Opin Oncol, 12(6), 582-7.
  20. Gonzalez CE, Couriel DR, Walsh TJ (1997 Feb). Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. [Review]. Clin Infect Dis, 24(2), 192-6.

Book Chapter

  1. Kitko CL, Couriel DR (). Chronic Graft vs Host Disease. In Abutalib S, Markman M (Eds.), Cancer consult: expertise for clinical practice (pp. 438-447). Wiley Blackwell.
  2. Carpenter PA, Couriel DR (). General Principles of Ancillary and Supportive Care. In Vogelsang GB, Pavletic SZ (Eds.), Chronic Graft Versus Host Disease: Interdisciplinary Management (pp. 157-68). Cambridge University Press.
  3. Couriel DR (). Diagnosis and Treatment of Graft Versus Host Disease. In Munker R, Lazarus H, Atkinson K (Eds.), The BMT Data Book (pp. 331-56). Cambridge University Press.
  4. Ghosh S, Couriel DR (). Complications of Bone Marrow Transplantation and Immunosuppression. In Shaw A, Riedel B, Burton A, Fields A, Freeley TW (Eds.), Acute Care of Cancer Patient (pp. 692-712). Informa Healthcare.
  5. Ghosh S, Couriel DR (). Complications of Immunosuppressive Treatment. In Perioperative Cancer Medicine: Anesthesia, Critical Care and Pain Control in Cancer Patients.
  6. Couriel DR, Sergio G (). Graft-Versus-Host Disease in Nonmyeloablative Transplant. In Ferrera J, Cooke K (Eds.), Graft-versus-Host Disease (pp. 511-23). New York: Marcel Dekker.

Conference Proceedings

  1. Carpenter PA, Kitko CL, Elad S, Flowers ME, Gea-Banacloche JC, Halter JP, Hoodin F, Johnston L, Lawitschka A, McDonald GB, Opipari AW, Savani BN, Schultz KR, Smith SR, Syrjala KL, Treister N, Vogelsang GB, Williams KM, Pavletic SZ, Martin PJ, Lee SJ, Couriel DR (2015 Jul). National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant, United States, 21(7), 1167-87.
  2. Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E, Moresi JM, Greenson J, Janin A, Martin PJ, McDonald G, Flowers ME, Turner M, Atkinson J, Lefkowitch J, Washington MK, Prieto VG, Kim SK, Argenyi Z, Diwan AH, Rashid A, Hiatt K, Couriel D, Schultz K, Hymes S, Vogelsang GB (2006 Jan). Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant, United States, 12(1), 31-47.
  3. Schultz KR, Miklos DB, Fowler D, Cooke K, Shizuru J, Zorn E, Holler E, Ferrara J, Shulman H, Lee SJ, Martin P, Filipovich AH, Flowers ME, Weisdorf D, Couriel D, Lachenbruch PA, Mittleman B, Vogelsang GB, Pavletic SZ (2006 Feb). Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant, United States, 12(2), 126-37.
  4. Couriel D, Carpenter PA, Cutler C, Bolanos-Meade J, Treister NS, Gea-Banacloche J, Shaughnessy P, Hymes S, Kim S, Wayne AS, Chien JW, Neumann J, Mitchell S, Syrjala K, Moravec CK, Abramovitz L, Liebermann J, Berger A, Gerber L, Schubert M, Filipovich AH, Weisdorf D, Schubert MM, Shulman H, Schultz K, Mittelman B, Pavletic S, Vogelsang GB, Martin PJ, Lee SJ, Flowers ME (2006 Apr). Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant, United States, 12(4), 375-96.
  5. Martin PJ, Weisdorf D, Przepiorka D, Hirschfeld S, Farrell A, Rizzo JD, Foley R, Socie G, Carter S, Couriel D, Schultz KR, Flowers ME, Filipovich AH, Saliba R, Vogelsang GB, Pavletic SZ, Lee SJ (2006 May). National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant, United States, 12(5), 491-505.

Case Report

  1. Dai E, Couriel D, Kim SK (2007 Jul). Bilateral marginal keratitis associated with engraftment syndrome after hematopoietic stem cell transplantation. Cornea, 26(6), 756-8.
  2. Gupta S, Jain A, Fanning TV, Couriel DR, Jimenez CA, Eapen GA (2006). An unusual cause of alveolar hemorrhage post hematopoietic stem cell transplantation: a case report. BMC Cancer, 6, 87.
  3. Qazilbash MH, Qu Z, Hosing C, Couriel D, Donato M, Giralt S, Champlin R (2005 Sep). Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia. Am J Hematol, 80(1), 43-5.
  4. Wong R, Durand JB, Luna MA, Couriel DR, Gajewski JL (2004 Mar 9). Images in cardiovascular medicine. Constrictive pericarditis in a patient with relapsed acute myelogenous leukemia after allogeneic bone marrow transplantation. Circulation, 109(9), e146-9.
  5. Wong R, de Lima M, Couriel D, Giralt S, Hosing C, Shahjahan M, Cheng YC, Bruton J, Champlin R, Khouri I (2003 May). Treatment of relapsing refractory diffuse large cell lymphoma after matched unrelated donor bone marrow transplant with immunosuppression withdrawal and rituximab. Leuk Lymphoma, 44(5), 829-32.

Editorial

  1. Couriel DR (2015 Apr). Extracorporeal photopheresis: Focus on therapeutic immunomodulation. Transfus Apher Sci, 52(2), 149-50.
  2. Khanna D, Georges GE, Couriel DR (2014 Jun 25). Autologous hematopoietic stem cell therapy in severe systemic sclerosis: ready for clinical practice? JAMA, 311(24), 2485-7.

Letter

  1. Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Ahmed I, Beitinjaneh A, Buchbinder D, Byrne M, Callander N, Chao N, Choi SW, DeFilipp Z, Gadalla SM, Gale RP, Gergis U, Hashmi S, Hematti P, Holmberg L, Inamoto Y, Kamble RT, Lehmann L, MacMillan MA, McIver Z, Nishihori T, Norkin M, OBrien T, Olsson RF, Reshef R, Saad A, Savani BN, Schouten HC, Seo S, Solh M, Verdonck L, Vij R, Wirk B, Yared J, Horowitz MM, Knight JM, Verneris MR (2018 Jan 30). Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation.LID - 10.1038/s41409-018-0100-1 [doi] [Letter to the editor]. Bone Marrow Transplant.
  2. Kanate AS, DiGilio A, Ahn KW, Al Malki M, Jacobsen E, Steinberg A, Hamerschlak N, Kharfan-Dabaja M, Salit R, Ball E, Bashir Q, Cashen A, Couriel D, Diez-Martin J, Katsanis E, Linhares Y, Mori S, Nash R, Pawarode A, Perales MA, Phipps CD, Richman C, Savani BN, Shapira MY, Stiff P, Strair R, Fenske TS, Smith SM, Sureda A, Olteanu H, Hamadani M (2017 Aug 2). Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis.LID - 10.1111/bjh.14879 [doi] [Letter to the editor]. Br J Haematol.
  3. Dytfeld D, Jasielec J, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R, Jakubowiak AJ (2014 Sep). Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma [Letter to the editor]. Haematologica, 99(9), e162-4.
  4. Oran B, Giralt S, Couriel D, Hosing C, Shpall EJ, de Meis E, Khouri IF, Qazilbash M, Anderlini P, Kebriaei P, Popat U, Carrasco-Yalan A, Champlin RE, de Lima M (2007 Dec). Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation [Letter to the editor]. Leukemia, 21(12), 2540-4.
  5. Wong R, Couriel D, Prieto VG (2003 Aug 15). The graft-versus-leukemia effect in leukemia cutis [Letter to the editor]. Transplantation, 76(3), 619-20.
  6. Andersson BS, Kashyap A, Couriel D, Madden T, de Lima M, Thall PF, Fernandez H, Vaughan WP, Jones R, Wingard JR, Blume KG, Champlin RE (2003 Nov). Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit [Letter to the editor]. Biol Blood Marrow Transplant, 9(11), 722-4.

Abstract

  1. Steven C Goldstein, MD, John Koreth, MBBS, DPhil, John M Magenau, MD, Robert J Soiffer, MD, Thomas Braun, PhD, Maggi Kennel, BS, MS, Reaha Goyetche, Attaphol Pawarode, MD, Mary M Riwes, DO, Joseph H Antin, MD, Corey S Cutler, MD, MPH, Vincent T Ho, MD, Edwin P Alyea III, MD, Brian L Parkin, MD, Gregory A Yanik, MD, Sung Won Choi, MD, Daniel R Couriel, MD, MS, John E Levine, MD, MS, Vedran Radojcic, MD, Charles Dinarello, MD, Pavan Reddy, MD (). Alpha 1 Anti-Trypsin (AAT): Novel Strategy to Treat Steroid Refractory Acute Graft Versus Host Disease [Abstract]. Biol Blood Marrow Transplant, 22(3), S57.
  2. Michael Boyer, MD, Pam Jacobson, James Marvin, Fen Fen Hsieh, Amber Preslar, Michael A Pulsipher, MD, Gerhard C Hildebrandt, MD, Axel Zander, MD, PhD, FACP, Daniel R Couriel, MD, MS, JoAnna Reems (). Reduced Intensity Haploidentical Stem Cell Transplantation with CD34 Selection and Addback of Regulatory and Conventional T Cells [Abstract]. Biol Blood Marrow Transplant, 22(3), S379-S380.
  3. Attaphol Pawarode, MD, Daniel R Couriel, MD, MS, Thomas Braun, PhD, John M Magenau, MD, Mary M Riwes, DO, Brian L Parkin, MD, Vedran Radojcic, MD, David Frame, PharmD, Sung Won Choi, MD, Pavan Reddy, MD, Steven C Goldstein, MD (). Phase 1 Study of Carfilzomib in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies [Abstract]. Biol Blood Marrow Transplant, 22(3), S346.
  4. Carrie L Kitko, MD, Thomas Braun, PhD, Charles Schuler, MD, Sung Won Choi, MD, Gregory Yanik, MD, Attaphol Pawarode, MD, John Magenau, MD, Austin Taylor, James LM Ferrara, MD, DSc, Daniel R Couriel, MD, MS, John Levine, MD, MS (). Phase II Clinical Trial of Etanercept Plus Extracorporeal Photopheresis GVHD Prophylaxis Following Unrelated Donor Reduced Intensity Transplantí [Abstract]. Biol Blood Marrow Transplant, 21(2), S337.
  5. Christina AM Smith, Tracey L Churay, Holly A Justman, Jessica K Yu, Attaphol Pawarode, MD, David Hanauer, MS, MD, John Magenau, MD, Steven C Goldstein, MD, Mary Mansour Riwes, DO, Brian Parkin, MD, John Levine, MD, MS, Daniel R Couriel, MD, MS (). The Graft-Versus-Lymphoma Effect in Diffuse Large B-Cell Lymphoma [Abstract]. Biol Blood Marrow Transplant, 21(2), S204-S205.
  6. Pawarode A, Braun T, Magenau J, Choi SW, Kitko CL, Yanik G, Goldstein SC, Couriel DR (). Allogeneic Hematopoietic Cell Transplant (Allo-HCT) for Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma: The University of Michigan Experience [Abstract]. Biol Blood Marrow Transplant, 20(2), S76.
  7. Raser K, McNulty ML, Yanik G, Goldstein SC, Magenau J, Pawarode A, Kitko CL, Hanauer D, Levine J, Couriel DR (). Routine Prophylaxis of Pneumocystis Jirovecii Pneumonia in Recipients of Autologous Hematopoietic Stem Cell Transplantation [Abstract]. Biol Blood Marrow Transplant, 20(2), S116-7.
  8. Churay TL, Justman HA, Skurka NL, Goldstein SC, Pawarode A, Magenau J, Couriel DR (). The Impact of Mold Infections after Allogeneic Transplantation [Abstract]. Biol Blood Marrow Transplant, 20(2), S218.
  9. Abedin S, Peres E, Levine JE, Yanik G, Pawarode A, Choi SW, Couriel DR (). Double Umbilical Cord Blood Transplantation after Novel Myeloablative Conditioning Using FluBu4/TLI [Abstract]. Biol Blood Marrow Transplant, 20(2), S211.
  10. Harris AC, Ferrara JLM, Braun T, Couriel DR, Choi S, Kitko CL, Goldstein SC, Magenau J, Paczesny S, Pawarode A, Reddy P, Yanik G, Taylor A, Connelly JA, Byersdorfer CA, Levine JE (). A Combination of Clinical Characteristics and Day 7 Biomarker Concentrations Predicts Graft-Versus-Host Disease Following Hematopoietic Cell Transplantation From Related Donors [Abstract]. Biol Blood Marrow Transplant, 19(2), S138-9.
  11. Yanik G, Magenau J, Goldstein SC, Pawarode A, Talpaz M, Levine J, Choi S, Kitko CL, Couriel DR (). A Prospective Study of Allogeneic Transplant for Older Patients with Acute Myelogenous Leukemia (AML) Indicates that Unrelated Donor Transplants are as Efficacious as Related Donor, with Favorable Outcomes for Intermediate Risk Disease [Abstract]. Biol Blood Marrow Transplant, 19(2), S232.
  12. Magenau J, Pawarode A, Couriel DR, Yanik G, Mineishi S, Braun T, Reddy P, Ferrara JLM, Frame D, Choi SW, Harris AC, Kitko CL, Connelly JA, Levine J, Goldstein SC (). Impact of Dose Intensification of FluBu2 to FluBu4 on Transplant Related Mortality, Relapse, and Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia in Remission [Abstract]. Biol Blood Marrow Transplant, 19(2), S226.
  13. Caram MV, Bellile EL, Englesbe M, Terjimanian M, Sonnenday C, Griggs JJ, Couriel DR (). The Impact of Sarcopenia on Transplant-Related Outcomes in Patients with Non-Hodgkin's and Hodgkin's Lymphoma [Abstract]. Biol Blood Marrow Transplant, 19(2), S234.
  14. Kitko CL, Saliba R, Choi SW, Reddy P, Goldstein SC, Magenau J, Pawarode A, Kennel M, Levine JE, White E, Couriel DR (). Biomarkers of Extracellular Matrix Remodeling in Chronic GVHD [Abstract]. Biol Blood Marrow Transplant, 19(2), S332.
  15. Vander Lugt M, Braun T, Hanash S, Ferrara JLM, Ritz J, Ho VT, Antin JH, Zhang Q, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel DR, Reddy P, Paczesny S (). Plasma ST2 Concentrations Predict Acute Gvhd Development and Non-Relapse Mortality [Abstract]. Biol Blood Marrow Transplant, 19(2, suppl), S142-3.
  16. Pawarode A, Mineishi S, Braun T, Ferrara JLM, Magenau J, Peres E, Yanik G, Reddy P, Levine JE, Choi SW, Kitko CL, Harris AC, Connelly JA, Goldstein SC, Couriel DR (). Phase 2 Study of Allogeneic Hematopoietic Cell Transplant (HCT) Following Intermediate-Intensity Fludarabine and Busulfan x 4 (FluBu4) Conditioning for High-Risk or Advanced Multiple Myeloma [Abstract]. Biol Blood Marrow Transplant, 19(2), S238.
  17. Frame D, Beechuk R, Markstrom D, Magenau J, Couriel DR (). Vitamin D Supplementation Decreases Grade 3-4 Acute GVHD in Allogeneic Transplants with Normal Baseline Levels [Abstract]. Biol Blood Marrow Transplant, 19(2), S324.
  18. Kitko CL, Saliba R, Paczesny S, Kennel M, Choi S, Reddy P, Levine J, Couriel DR (). Non-Relapse Mortality in Chronic Graft Versus Host Disease: Risk Factors At Onset and Reponse to Treatment [Abstract]. Biol Blood Marrow Transplant, 19(2), S332.
  19. Abedin S, Yanik GA, Magenau JM, Goldstein SC, Pawarode A, Levine JE, Kitko CL, Couriel DR (). Application Of BOS 0-Potential Criteria As a Predictor For Bronchiolitis Obliterans Syndrome In Allogeneic Stem Cell Transplant Patients [Abstract]. Blood, 122(21), 2060.
  20. Abedin S, Yanik G, Magenau J, Pawarode A, Goldstein SC, Kitko CL, White E, Couriel DR (). The Use of Early Spirometric Changes and IGF-1 Levels for the Detection of Patients at Risk for BOS [Abstract]. Biol Blood Marrow Transplant, 19(2), S316-7.
  21. Flowers MED, Hemmer MT, Li P, Cutler CS, Urbano-Ispizua A, Couriel DR, Gale RP, Inamoto Y, Antin JH, Bolwell BJ, Boyiadzis M, Cahn JY, Cairo MS, Isola LM, Jacobsohn DA, Jagasia M, Klumpp TR, Petersdorf EW, Santarone S, Schouten HC, Wingard JR, Spellman S, Weisdorf DJ, Pavletic, SZ, Lee SJ, Horowitz MM, Arora M (). The CIBMTR Chronic GVHD Risk Group Predicts Major Outcomes In An Independent Validation Cohort [Abstract]. Blood, 122(21), 706.
  22. Arai S, Arora M, Wang T, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Spellman S, Pavletic SZ (). Trends In Incidence, Presentation, and Outcomes Of Chronic Graft-Versus-Host Disease In Allogeneic Transplantation- Report From The Center For International Blood and Marrow Transplant Research [Abstract]. Blood, 122(21), 3309.
  23. Raser KJ, Yanik GA, Magenau JM, Goldstein SC, Pawarode A, Kitko CL, Levine JE, Hanauer D, Couriel DR (). Pneumocystis Jirovecii Pneumonia In Recipients Of Autologous Hematopoietic Stem Cell Transplantation: A 10-Year Cohort Study [Abstract]. Blood, 122(21), 3372.
  24. Choi S, DiPersio J, Braun T, Goldstein KS, Tawara I, Levine J, Sun Y, Couriel D, Krijanovski O, Chang L, Magenau J, Pawarode A, Kitko C, Paczesny S, Peres E, Mineishi S, Yanik GA, Lehmann M, Dinarello CA, Ferrara JLM, Reddy P (). Targeting Histone Deacetylases As a New Strategy for Graft Versus Host Disease Prevention [Abstract]. Blood, 120(21), 740.
  25. Yanik G, Magenau J, Mineishi S, Pawarode A, Alangaden K, Peres E, Goldstein S, Levine J, Choi S, Kitko C, Talpaz M, Couriel D (). Unrelated Donor Transplants for Older AML Patients Using a Low Dose TBI Containing Regimen Are As Efficacious As Related Donor Transplants, and Exhibit Favorable Outcomes for Intermediate Risk Disease [Abstract]. Blood, 120(21), 3119.
  26. Vander Lugt M, Braun TM, Hanash S, Ferrara JLM, Ritz J, Ho VT, Antin JH, Zhang Q, Chin A, Gomez A, Harris AC, Levine J, Choi S, Couriel D, Reddy P, Paczesny S (). Plasma ST2 Concentrations Predict Development of Acute Gvhd and Non-Relapse Mortality [Abstract]. Blood, 120(21), 466.
  27. Kitko C, Saliba RM, Paczesny S, Kennel M, Choi S, Reddy P, Levine J, Couriel D (). Risk Factors for Non-Relapse Mortality in Chronic Graft Versus Host Disease: Predicting Outcomes At Disease Onset [Abstract]. Blood, 120(21), 1941.
  28. Harris AC, Ferrara JLM, Braun TM, Couriel D, Choi S, Kitko C, Goldstein S, Magenau J, Paczesny P, Pawarode A, Reddy P, Yanik G, Taylor A, Connelly JA, Byersdorfer CA, Levine J (). An Algorithm Combining Clinical Characteristics and Day 7 Biomarker Concentrations Predicts Future Graft-Versus-Host Disease Following Related Donor Hematopoietic Cell Transplantation [Abstract]. Blood, 120(21), 463.
  29. Cooling L, Hoffmann S, Mineishi S, Couriel D (). High-Dose Cytarabine for Mobilization and Collection of Autologous Hematopoietic Progenitor Cells [Abstract]. American Society for Apheresis Annual Meeting.
  30. Lee SJ, Flowers ME, Martin PJ, Carpenter P, Hansen J, Chai X, Kurland B, Storer B, Arai S, Johnston L, Miklos D, Weisdorf D, Arora M, Majhail N, Cutler C, Jagasia M, Palmer J, Pidala J, Westervelt P, Pusic I, Giralt S, Goldberg J, Couriel D, Kitko C, Jacobsohn D, Pavletic SZ, Vogelsang GB, Gilman A, Schultz K (). Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD [Abstract]. Biol Blood Marrow Transplant, 17(8), 1114-20.
  31. Jakubowiak AJ, Dytfeld D, Jagannath S, Vesole DH, Anderson TA, Nordgren BK, Detweiler-Short K, Lebovic D, Stockerl-Ott KE, Griffith KA, Jobkar TL, Durecki DE, Wear SM, Ott RF, Al-Zoubi A, Mietzel MA, Hussein M, Couriel D, Leveque JA, Vij R (). Final Results of a Frontline Phase ½ Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM) [Abstract]. Blood, 118(21), 634.
  32. Vander Lugt MT, Braun T, Ferrara JLM, Hanash S, Levine JE, Wang CH, Zhang Q, Chin A, Harris AC, Choi SWJ, Couriel D, Reddy P, Paczesny S (). Plasma Concentration of ST2, the IL33 Receptor, At Initiation of Graft Versus Host Disease Therapy Predicts Day 28 Response and Day 180 Survival Post-Treatment [Abstract]. Blood, 118(21), 152.
  33. Berdeja JG, Couriel DR, Murphy P, Boccia RV, Priego V, Hainsworth JD, Macias-Perex IM, Flinn IW (). A Phase II Trial of Combined Bendamustine, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma (MM) Patients Who Are Not Candidates for High-Dose Chemotherapy: Results of a Planned Interim Safety Analysis [Abstract]. Blood, 118(21), 2943.
  34. Williams L, Couriel D, Mendoza T, McCarthy P, Neumann J, White M, Mobley G, Kapoor S, Hernandez L, Alousi A, Cleeland C (). A New Measure of Symptom Burden in Chronic Graft-Versus-Host Disease [Abstract]. Biol Blood Marrow Transplant, 16(2), S177.
  35. Paczesny S, Braun T, Vander Lugt M, Harris A, Fiema B, Hernandez J, Choi S, Kitko C, Magenau J, Yanik G, Peres E, Pawarode A, Mineishi S, Whitfield J, Jones D, Couriel D, Reddy P, Hanash S, Ferrara J, Levine J (). Three biomarker Panel at Day 7 and 14 Can Predict Development of Grade II-IV Acute Graft-Versus-Host Disease [Abstract]. Blood, 116(21), 675.
  36. Garcia-Manero G, Couriel DR, Tambaro FP, Gabrail N, Nadeem A, Kadia T, Jabbour E, Bathakur G, Faderl S, Newsome WM, Yang H, Stein K, Chen K, Kantarjian H (). A Phase II Randomized Bayesian Study of Very Low Dose Subcutaneous Decitabine Administered Daily or Weekly Times. Three in Patients with Lower Risk Myelodysplastic Syndrome (MDS) [Abstract]. Blood, 114(22), 119.
  37. Saliba RM, Couriel D, Komanduri K, Patah P, Westin J, Giralt S, Cooper L, Petropoulos D, Worth L, Safdar A, Champlin RE, Shpall EJ, de Lima M (). Incidence and Risk Factors for Chronic Graft-Versus-Host Disease (cGVHD) after Cord Blood Transplantation (CBT) [Abstract]. Biol Blood Marrow Transplant, 14(2), 132-3.
  38. Williams LA, Couriel DR, Neumann JL, Whisenant MS, Galbizo EO, Cleeland CS (). Defining the Symptom Burden of Chronic Graft Versus Host Disease [Abstract]. Biol Blood Marrow Transplant, 14(2), 164-5.
  39. Williams LA, Neumann JL, Couriel DR, Mendoza TR, White MH, Zhang Y, Cleeland CS (). Measuring the Symptom Burden of Chronic Graft Versus Host Disease [Abstract]. Biol Blood Marrow Transplant, 14(2), 56.
  40. Joseph RW, Jr, Komanduri KV, Saliba RM, Alousi A, Giralt S, Rondon G, Neumann J, Trevino C, Couriel DR, Champlin R, Popat U (). High Prevalence of Vitamin D Deficiency in Allogeneic Stem Cell Transplant Recipients [Abstract]. Blood, 112(11), 2138.
  41. de Lima M, Patah PA, Saliba R, Couriel D, Chan K, Worth L, Giralt S, Kebriae P, Khouri I, Cooper L, Fernandez-Vina M, Cano P, Petropoulos D, McMannis J, Hosing C, Rondon G, Komanduri KV, Champlin RE, Shpall EJ (). 2: Donor-Recipient Host-Versus-Graft Human Leukocyte Antigen Mismatches and Outcome of Cord Blood Transplants [Abstract]. Biol Blood Marrow Transplant, 13(11), 1393.
  42. Komanduri KV, St John LS, Bryan S, Martin S, McMannis JD, Molldrem JJ, Champlin RE, Cooper LJ, Worth L, Petropoulos D, Hosing C, Couriel D, de Lima M, Shpall EJ (). 20: Delayed Immune Recovery after Umbilical Cord Blood Transplantation (UCBT) Is Characterized By Thymic Regeneration Failure [Abstract]. Biol Blood Marrow Transplant, 13(11), 1400.
  43. Gulbis AM, Hsu Y, Neumann JL, Hymes S, Lima MJd, Hosing CM, Khouri IF, Qazilbash MH, Kebriaei P, Andersson BS, Champlin RE, Couriel D (). 296: Etanercept as salvage therapy for chronic graft-versus-host disease [Abstract]. Biol Blood Marrow Transplant, 13(2 suppl), 107-8.
  44. Westin JR, Saliba RM, de Lima M, Alousi A, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Champlin R, Couriel DR (). Risk Factors for Response after Initial Therapy for Acute Graft-Versus-Host-Disease (aGVHD) [Abstract]. Blood, 110(11), 5015.
  45. de Lima M, Andersson B, Fernadez-Vina M, Giralt S, Couriel D, Shpall E, Popat U, Qazilbash M, Alousi A, Cano P, Bosque D, Hosing C, Qureshi S, de Padua L, Munsell M, Anderlini P, Jones R, Westmoreland M, Gulbis A, Champlin R (). Prophylaxis of Graft-Versus-Host Disease (GVHD) with Pentostatin, Tacrolimus, and "Mini"-Methotrexate (MTX): A Phase I/II Controlled, Randomized Study in Unrelated Donor (UD) Transplantation [Abstract]. Blood, 110(11), 40.
  46. Couriel D, Patah P, Saliba R, Cooper L, Worth L, Petropoulos D, Depadua L, Zhang W, Giralt S, Champlin R, Shpall EJ, de Lima M (). Graft-Versus-Host Disease (GVHD) in Cord Blood Transplantation (CBT): Risk Factors, Clinical Manifestations and Outcomes [Abstract]. Blood, 110(11), 2977.
  47. Khouri IF, Saliba RM, Korbling M, Hosing C, Fayad L, Lee MS, Samaniego F, Samuels BI, Couriel D, Hagemeister F, McLaughlin P, Champlin RE (). Nonmyeloablative Allogeneic Transplantation (NMT) for Relapsed Follicular Lymphoma (FL): Continuous Complete Remission with Longer Follow-Up [Abstract]. Blood, 110(11), 485.
  48. Patah P, Saliba R, Fernandez-Vina M, Cano P, Pesoa S, Rondon G, Andersson B, Giralt S, Kebriaei P, Hosing C, Anderlini P, Couriel D, Alousi A, Padua L, Ramos C, Champlin R, de Lima M (). A Comparison of 1 Antigen-Mismatched Related and Matched Unrelated Transplants [Abstract]. Blood, 110(11), 3051.
  49. Qazilbash MH, Saliba RM, Parikh G, Hosing C, Mendoza F, Qureshi SP, Weber DM, Wang M, Flosser T, Couriel DR, Kebriaei P, Popat U, Alousi A, de Lima M, Champlin RE, Giralt S (). Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan Is Safe and Effective for Autotransplantation for Multiple Myeloma [Abstract]. Blood, 110(11), 942.
  50. Tam CS, Ledesma C, Korbling M, Fayad LE, Wang M, Alousi A, Hosing C, Kebriaei P, Rondon G, Giralt SA, Anderlini P, Popat U, Couriel D, Pro B, Samuels B, Hagemeister F, Champlin RE, Khouri IF (). Non-Myeloablative Allogeneic Stem Cell Transplantation (NMT) Overcomes the Adverse Effects of Treatment Resistance and High Beta-2-Microglobulin in Patients with Mantle Cell Lymphoma (MCL): An Analysis of 123 Transplantations at the MD Anderson Cancer Center [Abstract]. Blood, 110(11), 484.
  51. Qazilbash MH, Gul Z, Jindani S, Saliba R, Hosing C, Mendoza F, Qureshi SP, Weber DM, Wang M, Flosser T, Couriel D, de Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA (). 20: Autologous stem cell transplantation for elderly patients with multiple myeloma [Abstract]. Biol Blood Marrow Transplant, 13(2, suppl), 10.
  52. Qazilbash MH, Jindani S, Gul Z, Saliba R, Hosing C, Mendoza F, Qureshi SP, Weber DM, Wang M, Flosser T, Couriel D, Kebriaei P, Popat U, Alousi AM, de Lima M, Champlin RE, Giralt SA (). 19: Arsenic trioxide with ascorbic acid and high-dose melphalan for autologous hematopoietic stem cell transplantation for multiple myeloma [Abstract]. Biol Blood Marrow Transplant, 13(2, suppl), 9-10.
  53. Saliba RM, Komanduri K, Giralt S, Souza Jd, Patah PA, Oran B, Rondon G, Couriel D, Champlin R, Lima MD (). 269: Correlates and outcome of absolute lymphocyte count (ALC) on day 30 post allogeneic stem cell transplantation (SCT) for treatment of AML [Abstract]. Biol Blood Marrow Transplant, 13(2, suppl), 98.
  54. Trevino CM, Neumann J, Couriel D, Popat U, Hsu Y (). 419: Establishment of a long-term allogeneic blood and marrow program for early detection of complication and measuring outcomes [Abstract]. Biol Blood Marrow Transplant, 13(2), 149-50.
  55. Wang Y, Li D, Jones D, Bassett R, Sale GE, Khalili J, Komanduri KV, Couriel DR, Champlin RE, Molldrem JJ, Ma Q (). 309: Blocking LFA-1 activation with lovastatin prevents graft-versus-host disease in mouse bone marrow transplantation [Abstract]. Biol Blood Marrow Transplant, 13(2), 112-3.
  56. Qazilbash MH, Saliba R, Mendoza F, Roden L, Hosing C, Couriel D, Kebriaei P, Popat U, Lima MD, Champlin RE, Giralt SA (). Salvage non-myeloablative allogeneic transplantation after failure of an autologous transplantation in multiple myeloma [Abstract]. Biol Blood Marrow Transplant, 12(2, suppl 1), 117.
  57. Qazilbash MH, Saliba R, Mendoza F, Roden L, Hosing C, Couriel D, Kebriaei P, Popat U, DeLima M, Champlin RE, Giralt SA (). Salvage autologous transplantation in multiple myeloma [Abstract]. Biol Blood Marrow Transplant, 12(2, suppl 1), 121-2.
  58. Neumann JL, Trevino CM, Hsu Y, Popat U, Champlin RE, Couriel D (). Establishment of a long-term allogeneic blood and marrow follow-up program for early detection of complications and measuring outcomes [Abstract]. Biol Blood Marrow Transplant, 12(2, suppl 1), 164-5.
  59. Mickler KL, Saliba R, Ghosh S, Lima Md, Giralt S, Kim S, Andersson B, Khouri I, Champlin RE, Couriel D (). The risk of Graft-Versus-Host Disease (GVHD) varies with different myeloablative regimens: IV Busulfan/Fludarabine (IV BuFlu) versus IV Busulfan/Cyclophosphamide (IV BuCy) versus Fludarabine/Melphalan (FM) [Abstract]. Biol Blood Marrow Transplant, 12(2, suppl 1), 156-7.
  60. Couriel DR, Saliba RM, Ghosh S, Lima Md, Giralt S, Khouri I, Andersson B, Mickler K, Caldera Z, Hsu Y, Neumann J, Hymes S, Kim S, Champlin R (). Chronic or acute? GVHD beyond day 100 [Abstract]. Biol Blood Marrow Transplant, 12(2), 59.
  61. Kim SK, Couriel D, Ghosh S, Champlin R (). Ocular graft vs. host disease experience from MD Anderson Cancer Center: Newly described clinical spectrum and new approach to the management of stage III and IV ocular GVHD [Abstract]. Biol Blood Marrow Transplant, 12(2), 49-50.
  62. Saliba RM, Khouri IF, de Lima M, Hosing C, Okoroji G, Acholonou S, Maadani F, De Jesus J, Hsu Y, Champlin RE, Couriel DR (). Chronic Graft-Versus-Host (cGVHD) after Non-Myeloablative Stem Cell Transplantation (NST) with Rituximab-Containing Conditioning Regimens for Non-Hodgkin's Lymphoma [Abstract]. Blood, 108(11), 5316.
  63. Qazilbash MH, Saliba RM, Davis MS, Mendoza FL, Hosing C, Couriel DR, De Lima M, Kebriaei P, Weber DM, Wang M, Alousi AM, Matthes SG, Jones RB, Champlin RE, Giralt SA (). Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma [Abstract]. Blood, 108(11), 3090.
  64. Qazilbash MH, Saliba R, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA (). Autologous Stem Cell Transplantation for Elderly Patients with Multiple Myeloma [Abstract]. Blood, 108(11), 5422.
  65. Patah PA, Gurkan E, Saliba R, de Lima M, Rondon G, Ramos CA, Couriel D, de Souza JA, Champlin R, Lichtiger B (). "Prophylactic" Platelet (PLT) Transfusions in the Setting of Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT): Similar Clinical Efficacy of Single Donor (SDP) and Random Donor Pooled (RDP) Platelet Products [Abstract]. Blood, 108(11), 597.
  66. Komanduri KV, St John LS, Bryan S, Martin S, McMannis JD, Molldrem JJ, Champlin RE, Cooper LJ, Worth L, Petropoulos D, Couriel DR, de Lima M, Shpall EJ (). Delayed Immune Recovery after Umbilical Cord Blood Transplantation (UCBT) Is Characterized by Thymic Regeneration Failure [Abstract]. Blood, 108(11), 312.
  67. Khouri IF, Saliba RM, Hosing C, Valverde R, Erwin WD, Fayad L, Maadani F, Korbling MJ, Okoroji G-J, Stachowiak AM, Samuels BI, Anderlini P, Couriel DR, de Lima M, Giralt S, Popat U, Kebriaei P, Ueno NT, Qazilbash MH, McLaughlin PW, Hagemeister FB, Younes A, Podoloff DA, Champlin RE (). Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin's Lymphoma (NHL) [Abstract]. Blood, 108(11), 315.
  68. Kebriaei P, Giralt S, Madden TL, Thapar N, Shpall EJ, Hosing C, Qazilbash MH, Couriel DR, Popat U, Thall PF, Champlin RE, Jones R, Andersson BS (). Toxicity and Early Response after Intravenous (IV) Busulfan (Bu) Plus Melphalan (Mel) Conditioning for Autologous Stem Cell Transplantation (SCT) in Patients (pts) with Multiple Myeloma (MM) [Abstract]. Blood, 108(11), 2943.
  69. Kebriaei P, Detry M, Carrasco-Yalan A, Anagnostopoulos A, Couriel D, Khouri I, Anderlini P, Hosing C, Alousi A, Giralt S, Champlin R, de Lima M (). Long-Term Follow-Up of Allogeneic Stem Cell Transplantation (SCT) with Reduced Intensity Conditioning (RIC) for Patients (pts) with Chronic Myeloid Leukemia (CML) [Abstract]. Blood, 108(11), 2898.
  70. Hosing C, Saliba RM, Okoroji G-J, Popat U, Couriel D, Kebriaei P, Ali T, De Lima M, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I (). High-Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Transplantation (AHCT) for Non-Hodgkin's Lymphoma (NHL) in Patients over 65 Years of Age [Abstract]. Blood, 108(11), 3059.
  71. 116 de Lima M, Wang X, Thall PF, Couriel D, Jones RB, Shpall EJ, Popat U, Giralt S, Korbling M, Champlin R, Andersson BS (). Long-Term Follow-Up of IV Busulfan (Bu) with Fludarabine (Flu) vs IV Bu with Cyclophosphamide (Cy) as Pre (Allogeneic) Transplant Conditioning Therapy for AML/MDS [Abstract]. Blood, 108(11), 322.
  72. de Lima M, Patah PA, Saliba R, Couriel D, Chan K, Worth L, Giralt S, Kebriae P, Khouri I, Cooper L, Fernandez-Vina M, Cano P, Petropoulos D, McMannis J, Hosing C, Rondon G, Komanduri KV, Champlin RE, Shpall EJ (). Donor-Recipient Host-Versus-Graft (HVG) HLA Mismatches and Outcome of Cord Blood Transplants (CBT) [Abstract]. Blood, 108(11), 436.
  73. de Lima M, Parmar S, Liu P, Patah PA, Cano P, Shpall EJ, Hosing C, Couriel D, Anderlini P, Giralt S, Andersson BS, Kebriaei P, Rondon G, Champlin R, Fernandez-Vina M (). HLA-DP Mismatches Increase the Risk of Acute GVHD after Unrelated Donor Hematopoietic Transplantation (UDT) [Abstract]. Blood, 108(11), 3125.
  74. Anderlini P, Saliba RM, Acholonu S, Giralt SA, Khouri IF, Andersson B, De Lima M, Hosing C, Couriel D, Champlin RE (). Two-Year Follow-Up Results at the M.D. Anderson Hospital with Reduced-Intensity Allogeneic Stem Cell Transplantation with Fludarabine-Melphalan as Preparative Regimen in Relapsed/Refractory Hodgkin's Lymphoma: Comparable Outcome with Matched Related and Unrelated Donors [Abstract]. Blood, 108(11), 3115.
  75. Ahmed B, Saliba RM, Ashraf N, Mendoza F, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH (). Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant [Abstract]. Blood, 108(11), 3101.
  76. Popat UR, de Lima M, Anderlini P, Andersson B, Couriel D, Hosing C, Kebriaei P, Qazilbash M, Alousi A, Champlin R, Giralt S (). Long-term survival of patients with AML in remission after reduced intensity allogeneic hematopoietic stem cell transplantation (RISCT) [Abstract]. ASH Clinical Science Symposium.
  77. Saliba RM, de Lima M, Hosing C, Khouri IF, Giralt S, Anderlini P, Ghosh S, Mickler K, Ippoliti C, Caldera Z, Hsu Y, Neumann J, Champlin R, Couriel DR (). Clinical, prognostic and therapeutic implications in the diagnosis of grade I acute graft-versus-host disease [Abstract]. Blood, 106(11), 1799.
  78. Qazilbash MH, Davis MS, Aleman A, Roden L, Libuano F, Thall PF, Wang X, Couriel D, de Lima M, Hosing C, Kebriaei P, Weber D, Wang M, Jones RB, Matthes SG, Champlin RE, Giralt S (). Arsenic trioxide with ascorbic acid and high-dose melphalan: A new preparative regiman for autologous hematopoietic stem cell transplantation for multiple myeloma [Abstract]. Blood, 106(11), 1159.
  79. Couriel DR, Thall P, Mickler K, de Lima M, Giralt S, Qazilbash MH, Hosing C, Khouri I, Kebriaei P, Hsu Y, Saliba R, Ippoliti C, Champlin R (). Phase II/III randomized study comparing two different tacrolimus blood levels for the prevention of graft-versus-host disease (GVHD) [Abstract]. Blood, 106(11), 142.
  80. Kebriaei P, Saliba RM, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S, Qazilbash MH, Gajewski JL, Ha CS, Champlin RE, Khouri I (). The impact of reituximab in the development of acute graft versus host disease (GVHD) following allogeneic stem cell transplantation (SCT) for acute lymphoblastic leukemia (ALL) [Abstract]. Blood, 106(11), 1803.
  81. Khouri IF, Tarrand JJ, Okoroji GJ, Salia RM, Hosing CM, Couriel DR, Kebriaei P, Friggith D, Rondon G, Ippoliti C, Champlin RE (). Campath-IH combined with fludarabine/cyclophosphamide/rituximab (FCR) as conditioning for unrelated non-myeloablative hematopoietic transplantation (NMT) for non-hodgkin’s lymphoma (NHL): Low mortality rate and lower than expected incidence of cytomegalovirus (CMB) reactivation [Abstract]. Blood, 106(11), 2902.
  82. Hosing C, Saliba RM, de Lima M, Giralt S, Ghosh S, Hsu Y, Anderlini P, Hymes S, Andersson B, Khouri I, Champlin R, Couriel DR (). Secondary Malignancy after Allogeneic Stem Cell Transplantation: Incidence and Risk Factors [Abstract]. Blood, 106(11), 1123.
  83. Jabbour E, Shahjahan M, Rondon G, Anderlini P, Giralt S, Couriel DR, Champlin R, Khouri I (). Treatment of Graft Failure with Fludarabine, Antithymocyte Globulin and a Second Allogeneic Stem Cell Transplantation [Abstract]. Blood, 106(11), 2734.
  84. Parmar S, Fernandez-Vina M, Liu P, Cano P, Andersson BS, Munsell M, Giralt S, McMannis J, Shpall EJ, Couriel D, Gosh S, Champlin R, de Lima M (). Influence of allele level HLA typing on unrelated donor transplantation for high risk myeloid leukamias [Abstract]. Blood, 106(11), 2916.
  85. Oran B, Saliba R, Giralt S, Couriel DR, Carrasco-Yalan A, Hosing c, Shahjahan M, de Meis E, Anagnostopoulos A, Anderlini P, Gosh S, Khouri I, Champlin R, de Lima M (). Long-term follow up of allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan reduced intensity conditioning for high rick AML/MDS [Abstract]. Blood, 106(11), 838.
  86. Oran B, Giralt S, Shahjahan M, Anagnostopoulos A, Couriel D, Kebriaei P, Hosing C, Ghosh s, de Meis E, Donato M, Ativitavas T, Carrasco-Yalen A, Champlin R, de Lima M (). Natural history of AML/MDS relapsing after allogeneic hematopoietic stem cell transplantation using reduced intensity preparative regimens [Abstract]. Blood, 106(11), 2019.
  87. de Lima M, Couriel DR, Ghosh S, Jones R, Shpall EJ, Giralt S, Hosing C, Kebriaei P, Champlin R, Andersson BS (). Outcomes of older patients with myeloid leukemias treated with myeloablative intravenous busulfan – based conditioning [Abstract]. Blood, 106(11), 660.
  88. de Lima M, Giralt S, Caldera Z, McCormick G, Qazilbash M, Anderlini P, Shpall EJ, Hosing C, Donato M, Kornblau S, Khouri I, Martin T, Couriel D, Champlin R (). Results of a phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for relapsed myeloid leukemias [Abstract]. Blood, 106(11), 941.
  89. Escalon MP, Saliba RM, Hsu Y, Ghosh S, Ippoliti C, Hosing C, de Lima MJ, Neumann JL, Champlin RE, Couriel DR (). Sirolimus in combination with tacrolimus for the treatment of resistant chronic graft-versus-host disease [Abstract]. J Clin Oncol, 23(16S), 599s.
  90. Thall PF, Wooten LH, Couriel DR, Champlin RE (). An Adaptive Bayesian Design for a Randomized Trial of High-Versus-Low-Level Tacrolimus as Prophylaxis for Graft-Versus-Host Disease in Allogeneic Stem Cell Transplantation [Abstract]. Biol Blood and Marrow Transplant, 11(2), 107.
  91. de Lima M, Couriel DR, Shahjahan M, Alamo J, Madden T, Thapar N, Russell J, Anderlini P, Giralt S, Shpall E, Jones R, Champlin R, Andersson B (). Pretransplant Conditioning with IV Busulfan (BU) and Fludarabine (FLU) as Alternative to BU and Cyclophosphamide (CY)—A Safe, Myeloablative Regimen with High Antileukemic Efficacy in AML/MDS [Abstract]. Biol Blood and Marrow Transplant, 11(2), 63.
  92. Couriel DR, Hosing C, Anderlini P, Ippoliti C, Hsu Y, Neumann J, de Lima MJ, Ghosh S, Rhodes B, Saliba R, Champlin R, Donato M (). Extracorporeal Photochemotherapy (ECP) for the Treatment of Chronic Graft-versus-Host Disease [Abstract]. Biol Blood and Marrow Transplan, 11(2), 48.
  93. Alamo JG, Shahjahan M, Wong RS, de Lima M, Khouri I, Gajewski J, Couriel DR, Andersson, BS, Anderlini P, Champlin R, Giralt S (). Prognostic Factors for Allogeneic Stem Cell Transplantation (ASCT) for Untreated First Relapse of Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) [Abstract]. Biol Blood and Marrow Transplant, 11(2), 38-9.
  94. Couriel DR, Saliba R, de Lima MJ, Hosing C, Andersson B, De Jesus J, Mickler K, Hsu Y, Shpall EJ, Neumann J, Ghosh S, Champlin R (). Hyperacute GVHD: Analysis of Risk Factors, Clinical Manifestations, and Outcomes [Abstract]. Biol Blood and Marrow Transplant, 11(2), 11.
  95. Khouri I, Saliba R, Kebriaei P, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S, Qazilbash M, Gajewski J, Champlin R (). Allogeneic Transplantation for Adult Acute Lymphoblastic Leukemia (ALL) with Rituximab or Campath I-H [Abstract]. Blood, 104(11), 366b.
  96. Khouri I, Saliba R, Couriel DR, Okoroji G, Acholonu S, Maadani F, Champlin R (). Effect of Rituximab on the Incidence of GVHD in Lymphoma Patients Who Received the BEAM-Conditioning and an Allogeneic Stem Cell Transplantation [Abstract]. Blood, 104(11), 326b.
  97. Qazilbash M, Saliba R, de Lima M, Couriel DR, Hosing C, Aleman A, Lei X, Champlin R, Giralt S (). Second Autologous or Allogeneic Transplantation after the Failure of First Autograft in Multiple Myeloma [Abstract]. Blood, 104(11), 909a.
  98. de Lima M, Shahjahan M, Alamo J, Williams, P, von Wolff B, Couriel DR, Khouri I, Rondon G, Wheeler B, Estey E, Ueno N, Kebriaei P, Champlin R, Giralt S (). Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients Aged 65 Years or Older with AML and MDS [Abstract]. Blood, 104(11), 632a.
  99. de Lima M, Thall P, Shahjahan M, Xuemei W, Couriel DR, Anderlini P, Hosing C, Qazilbash M, McCormick G, Ippoliti C, Donato M, Martin T, Metoyer L, Griffin L, Kebriaei, P, Champlin R, Giralt S (). Phase I/II Study of Gemtuzumab Ozogamicin (GO), Fludarabine and Melphalan (FM) Conditioning Regiment for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in AML/MDS [Abstract]. Blood, 104(11), 505a.
  100. Shpall E, de Lima M, Chan K, Champlin R, Gee A, Thall P, Komanduri K, Couriel DR, Andersson B, Hosing C, Giralt S, Karandish S, Sadeghi T, Muriera B, Peled T, Grynspan F, Nagler A, McMannis J (). Transplantation of Cord Blood Expanded Ex Vivo with Copper Chelator [Abstract]. Blood, 104(11), 281a.
  101. Couriel DR, Saliba R, de Lima M, Hosing C, Andersson B, deJesus J, Mickler K, Hsu Y, Shpall E, Ghosh, S, Champlin R (). Hyperacute Graft-Versus-Host Disease: Analysis of Risk Factors, Clinical Manifestations and Outcomes [Abstract]. Blood, 104(11), 210a.
  102. de Lima M, Couriel DR, Munsell M, Westmoreland M, Shah H, deJesus J, Hosing C, Ghosh S, Anderlini P, Gajewski J, Andersson B, Kornblau S, Hocking B, Ippoliti C, Giralt S, Shpall E, Champlin R (). Pentostatin, Tacrolimus, and “Mini”-Methotrexate for Graft-Versus-Host Disease (GVHD) Propjylaxis: A Phase I/II Controlled, Randomized Study [Abstract]. Blood, 104(11), 208a.
  103. Qazilbash M, Wieder E, Rios R, Lu S, Kant S, Giralt S, Estey E, Thall P, de Lima M, Couriel DR, Champlin R, Komanduri K, Molldrem J (). Vaccination with the PR1 Leukemia-Associated Antigen Can Induce Complete Remission in Patients with Myeloid Leukemia [Abstract]. Blood, 104(11), 77a.
  104. de Lima M, Couriel DR, Shahjahan M, Alamo J, Thall P, Russell J, Anderlini P, Giralt S, Shpall E, Jones R, Champlin R, Andersson B (). IV Busulfan (Bu) with Fludarabine (Flu) or Cyclophosphamide (Cy) – Comparing Ablative Conditioning Regimens for Allogeneic Transplantation in AML/MDS [Abstract]. Blood, 104(11), 30a-1a.
  105. Cheng YCC, Rondon G, Couriel DR, de Lima MJ, Hosing C, Khouri IF, Giralt SA, Gajewski JL, Champlin RE, Ueno NT (). Interleukin-2 (IL-2) with high-dose chemotherapy (HDC) and autologous hematopoietic stem-cell transplantation (AHST) for poor-risk metastatic breast cancer (MBC) [Abstract]. J Clin Oncol, 23, 6664.
  106. De Jesus J, Ghosh S, Hsu Y, Neumann J, Cohen A, Champlin R, Couriel DR (). Tacrolimus in combination with steroids for the treatment of chronic GvHD [Abstract]. Biol Blood and Marrow Transplant, 10(2), 49-50.
  107. Gajewski J, Cano P, Saliba R, Giralt S, Khouri I, Ma Y, Shahjahan M, Couriel DR, Andersson B, Champlin RE (). Impact of allele level molecular HLA typing on non-myeloablative unrelated donor bone marrow transplants [Abstract]. Experimental Hematology, 31(7), 28S.
  108. Anderlini P, Acholonu S, Okoroji G, Giralt S, Ueno N, Donato M, Andersson B, Khouri I, Couriel DR, Champlin RE (). Fludarabine-based, reduced intensity conditioning allows minimal early transplant related mortality following allogeneic stem cell transplantation from matched related and unrelated donors in advanced Hodgkin’s disease [Abstract]. Experimental Hematology, 31(7), 25S.
  109. Kim SK, Couriel DR, Combos D, Esmaeli B (). Early topical steroid treatment for grade IV acute ocular graft-vs-host disease (GVHD) with corneal epithelial sloughing [Abstract]. Investigative Ophthalmology and Visual Science, 44, 1387S.
  110. Hsu Y, Cohen A, Couriel DR (). Eosinophilia as a Presenting Sign for Chronic Graft Versus Host Disease after Allogeneic Bone Marrow Transplantation [Abstract]. Blood, 102(11), 462b.
  111. Lee BN, Andersson V, Cohen MZ, Mendoza T, de Lima M, Couriel DR, Brown BW, Wang XS, Cleeland CS, Giralt S, Champlin RE, Reuben JM (). Relationship between Plasma Cytokine Levels and Self-Reported Symptoms in AML Patients Pre-and Post-Transplantation with Allogeneic Peripheral Blood Stem Cells [Abstract]. Blood, 102(11), 966a.
  112. Madden T, Nguyen J, Thapar N, Couriel DR, de Lima M, Pierre B, Espinosa L, Champlin RE, Andersson B (). The Pharmacokinetics (PK) of Once Daily Intravenous (IV) Busulfan (Bu) as Part of Pre-transplant Preparative Regimens; a Comparison to Q 6 Hourly Dosing [Abstract]. Blood, 102(11), 477a.
  113. Espirito J, Hicks KL, Ghosh S, Couriel DR (). Evaluation of the Use of Synagis (Palivizumab) for Treatment of Respiratory Syncytial Virus Infection in Bone Marrow Transplant Recipients [Abstract]. Blood, 102(11), 973a.
  114. Khouri IF, Saliba RM, Acholonu S, Okoroji GJ, Hosing C, Fayad L, Couriel DR, Pro B, Giralt S, Andersson B, Younes A, McLaughlin P, Champlin RE (). Improved Outcome with High-Dose Rituximab (HD-R) with G/GM-CSF and Autologous Stem Cell Transplantation (ASCT) for Relapsed Aggressive B-Cell Non-Hodgkin’s Lymphomas (NHL): The Impact of Histologies of Follicular (FL) Origin [Abstract]. Blood, 102(11), 735a.
  115. Couriel DR, Saliba R, Ghosh S, de Lima M, Hosing C, Khouri I, Giralt S, Cohen A, Champlin RE (). Early Acute GVHD: Syndrome and Clinical Implications [Abstract]. Blood, 102(11), 712a.
  116. Couriel DR, Carrasco A, Saliba R, Ghosh S, De Lima M, Hosing C, Khouri I, Andersson B, Champlin R, Cleary K (). GvHD of the Liver: A Clinicopathological Analysis [Abstract]. Blood, 102(11), 712a.
  117. de Lima M, Madden T, Couriel DR, Thall PF, Shahjahan M, Giralt S, Anderlini P, Russell J, Shpall EJ, Champlin RE, Andersson BS (). Once daily busulfan (Bu) and fludarabine (FLU) with allogeneic stem cell transplantation (AlloSCT) in acute myelogenous leukemia (AML) and myelodysplastics syndrome (MDS): Clinical results and pharmacokinetics [Abstract]. Blood, 102(11), 704a.
  118. El-Zimaity M, Saliba R, Chan K, Shahjahan M, Carrasco A, Khorshid O, Caldera H, Couriel DR, Ippoliti C, Hosing C, Champlin R, de Lima M (). Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: Donor type matters [Abstract]. Blood, 102(11), 432b.
  119. de Lima M, Carrasco A, Lee MS, Saliba R, Glassman A, Anagnostopoulos A, Couriel DR, Caldera H, Andersson BS, El-Zimaity M, Giralt S, Champlin R (). Mixed chimerism after allogeneic hematopoietic stem cell transplantation (hsct) for acute myeloid leukemia (aml) and myelodysplastic syndrome (mds) [Abstract]. Blood, 102(11), 707a.
  120. Hicks K, Ippoliti C, Giralt S, de Lima MJ, Cohen A, Donato M, Khouri I, Champlin R, Couriel DR (). Predominance of resistant gram positive isolates as sources of bacteremia in GvHD patients treated with Infleximab [Abstract]. Biol Blood and Marrow Transplant, 9(2), 133.
  121. Couriel DR, Hicks K, Giralt S, Ippoliti C, Khouri I, De Lima M, Horton E, Cohen A, Hosing C, Donato M, Anderlini P, Molldrem JJ, Gajewski J, Champlin R (). Phase III Trial with Infliximab/methypredisolone (MP) vs. MP for the treatment of acute GvHD: Preliminary findings [Abstract]. Biol Blood and Marrow Transplant, 9(2), 95.
  122. Couriel DR, Hicks K, Saliba R, Cohen A, Ippoliti C, Hsu Y, Donato M, Giralt S, Khouri I, Hosing C, De Lima MJ, Andersson B, Gajewski J, Neumann J, Champlin R (). Sirolimus(Rapamycin) for treatment of Steroid-refractory chronic GvHD [Abstract]. Biol Blood and Marrow Transplant, 9(2), 67-8.
  123. Neumann JL, Hsu Y, Tallarigo J, Champlin R, Couriel DR (). Quality of life in patients with chronic GvHD: A quality process improvement in blood and marrow transplantation [Abstract]. Biol Blood and Marrow Transplant, 9(2), 119.
  124. Lee B, Couriel DR, Shen D, Hinze L, Champlin R, Reuben JM (). Serum Cytokine Profiles of Patients with Acute GvHD treated with Methylprednisolone alone or in combination with Infliximad are different [Abstract]. Biol Blood and Marrow Transplant, 9(2), 98-9.
  125. Anderlini P, Acholonu S, Okoroji GJ, Giralt S, Ueno N, Donato M, Andersson BS, Khouri I, Couriel DR, Ippoliti C, Valverde RB, Champlin R (). Reduced early transplant-related mortality following allogeneic stem cell transplantation (SCT) with fludarabine-based, reduced-intensity conditioning from matched related and unrelated donors in advanced Hodgkin’s Disease (HD) [Abstract]. Biol Blood and Marrow Transplant, 9(2), 71.
  126. de Lima M, Saliba R, Carrasco A, Shahjahan M, Couriel DR, Anagnostopoulos A, Hosing C, Shah H, de Meis E, Champlin R, Giralt S (). Long-Term Follow-up Of Patients with AML and MDS treated with Reduced-Intensity (RI) or Non-Myeloablative (NMA) conditioning regimens and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) [Abstract]. Blood, 102(11), 724a.
  127. Andersson B, Madden T, Shahjahan M, de Lima M, Couriel DR, Gajewski J, Giralt S, Donato M, Russell J, Champlin RE (). Early data using fludarabine and IV busulfan ATG as myeloablative, yet reduced toxicity conditioning regimen for allogeneic transplantation in AML and MDS [Abstract]. Bone Marrow Transplantation, 29(S2), 75s.
  128. de Lima M, Saliba RM, Ma C, Shahjahan M, Giralt S, Donato M, Couriel DR, Khouri I, de Meis E, Andersson BS, Champlin RE, Gajewski J (). Analysis of one antigen mismatched related transplants for advanced stage myeloid leukemias [Abstract]. Blood, 100(11), 857a, 3380.
  129. de Lima M, Couriel DR, Shahjahan M, Madden T, Gajewski J, Giralt S, Russell J, Champlin RE, Andersson BS (). Allogeneic transplantation for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) using a low-toxicity combination of intravenous (IV) Busulfan (Bu) and Fludarabine (Flu) +/- ATG [Abstract]. Blood, 100(11), 853a, 3366.
  130. de Lima, M, Wong R, Martin T, Couriel DR, Anagnostopoulos A, Shahjahan M, Hosing C, Andersson B, Donato M, Cano P, Ippoliti C, Estey E, Gajewski J, Champlin RE, Giralt S (). Unrelated donor hematopoietic stem cell transplantation (HSCT) for the treatment or myeloid malignancies in patients older than 55 years of age [Abstract]. Blood, 100(11), 2526.
  131. Anagnostopoulos A, de Lima M, Munsell M, Shahjahan M, Couriel DR, Martin T, Cano P, McMannis J, Gajewski J, Andersson B, Champlin RE, Giralt S (). Unrelated donor bone marrow transplantation (UDR) for adults with AML/MDA: Similar outcomes with ablative or reduced intensity preparative regimens [Abstract]. Blood, 100(11), 635a-6a, 2502.
  132. Anderlini P, Acholonu S, Okoroji GJ, Giralt S, Ueno N, Donato M, Andersson BS, Khouri I, Couriel DR, Ippoliti C, Valverde RB, Champlin RE (). Reduced early transplant-related mortality following allogeneic stem cell transplantation with fludarabine based, reduced intensity conditioning from matched related and unrelated donors in advanced Hodgkin’s disease [Abstract]. Blood, 100(11), 620a, 2444.
  133. Khouri IF, Lee MS, Saliba RM, Gu J, Fayad L, Hosting C, Donato ML, Pro B, Couriel DR, Rodriguez M, Korbling M, Cabanillas F, Ruth K, Champlin RE (). Nonablative allogeneic stem cell transplantation for relapsed mantle cell lymphoma (MCL): A promising strategy for an aggressive disease [Abstract]. Blood, 100(11), 1652.
  134. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, Couriel D, de Lima M, Donato ML, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning JT, Pro B, Shpall E, Youness A, McLaughlin P, Champlin RE (). Concurrent administration of high- dose rituximab (HD-R) with G/GM-CSF and autologous Stem cell Transplantation for relapsed B cell lymphomas: Increased efficacy without added toxicity [Abstract]. Blood, 100(11), 645a.
  135. de Lima M, Wong R, Martin T, Couriel DR, Anagnostopoulos A, Shahjahan M, Hosing C, Andersson B, Donato M, Cano P, Ippoliti C, Estey E, Gajewski J, Champlin R, Giralt S (). Unrelated donor hematopoietic stem cell transplantation (HSCT) for the treatment of myeloid malignancies in patients older than 55 years of age [Abstract]. Blood, 100(1), 642a.
  136. Gajewski J, Cano P, Saliba RM, Khouri I, Giralt S, Ma Y, Shahjahan M, Couriel DR, Andersson B, Champlin R (). Impact of high resolution molecular HLA typing and ATG on outcomes of non-myeloablative unrelated donor Bone Marrow Transplantation [Abstract]. Blood, 100(11), 466b.
  137. Khouri I, Sheng LM, Saliba R, Jun G, Fayad L, Hosing C, Donato M, Pro B, Couriel DR, Rodriguez M, Krbling M, Cabanillas F, Ruth K, Champlin R (). Nonablative allogeneic stem cell transplantation for relapsed mantle cell lymphoma (MCL): A promising strategy for an aggressive disease [Abstract]. Blood, 100(1), 426a-7a.
  138. Hosing C, de Lima M, Saliba RM, Shahjahan M, Couriel DR, Andersson B, Giralt S, Champlin RE (). Second allogeneic hematopoietic stem cell transplantation (HSCT) in patients with refractory hematopoietic malignancies [Abstract]. Blood, 100(11), 430a, 1666.
  139. Couriel DR, Saliba R, Hicks K, Cohen A, Ippoliti C, Neumann J, Giralt, S, de Lima M, Champlin R (). TNF-alpha inhibition for the treatment of chronic GvHD [Abstract]. Blood, 100(11), 847a.
  140. Couriel DR, Hicks K, Saliba R, Cohen A, Ippoliti C, Donato M, Anderlini P, Giralt S, Khouri I, Hosing C, de Lima M, Andersson B, Neumann J, Champlin R (). Sirolimus (Rapamycin) for treatment of steroid-refractory chronic graft versus host disease [Abstract]. Blood, 100(11), 847a.
  141. Madden T, de Lima M, Shahjahan M, Pierre B, Gajewski JL, Giralt S, Donato ML, Russell JA, Champlin RE, Andersson BS, Couriel DR (). Pharmacokinetics of once daily IV Busulfan in a myeloablative/reduced toxicity conditioning regimen for allogeneic transplantation in myeloid leukemia [Abstract]. Second International Conference on High Dose Chemotherapy Innovation and Evolution.
  142. Gajewski JL, Khouri I, Champlin RE, Saliba RM, McMannis JD, Donato ML, Ueno N, Couriel DR, Shahjahan M, Ma Y, Giralt SA (). Anti-thymocyte globulin (ATG) reduces primary graft failure (GF) risk and may reduce acute graft versus hot disease (aGvHD) in 212 non-myeloablative blood and marrow transplant (BMT) patients (pts) receiving unrelated or 1 antigen (Ag) mismatched (MM) related donor grafts [Abstract]. J Clin Oncol, 21, 1676.
  143. Couriel DR, Hicks K, Ippoliti C, de Lima M, Donato M, Cohen A, Andersson B, Hosing C, Giralt S, Champlin R (). Tumor necrosis factor alpha blockage with infliximab in the treatment of acute graft-versus host disease (GvHD): An update [Abstract]. Biol Blood and Marrow Transplant, 8(2), 85.
  144. Couriel DR, Giralt S, Khouri I, Andersson B, Cohen A, de Lima M, Saliba R, Champlin R (). Graft-versus-host disease (GvHD) after non-myeloablative (NMA) vs myeloablative (MA) conditioning in fully matched sibling donor transplants: An update [Abstract]. Biol Blood and Marrow Transplant, 8(2), 85.
  145. Wong R, Hicks K, Ippoliti C, Giralt S, de Lima M, Cohen A, Khouri I, Champlin R, Couriel DR (). Tumor necrosis factor alpha blockade in the treatment of graft-versus-host disease: an update on infectious complications [Abstract]. Biol Blood and Marrow Transplant, 8(2), 91.
  146. de Lima M, Shahjahan M, Madden T, Couriel DR, Gajewski JL, Giralt S, Donato ML, Russell JA, Champlin RE, Andersson BS (). Reduced toxicity conditioning therapy with fludarabine and IV busulfan ATG for allogeneic transplantation in AML and MDS; preliminary results [Abstract]. Biol Blood and Marrow Transplant, 8(2), 76.
  147. Martin T, Shahjahan M, de Lima M, Couriel DR, Champlin R, Gajewski J, Giles F, Kantarjian H, Andersson B, Giralt S (). The use of mylotarg as anti-leukemia therapy increases the incidence of liver toxicity including VOD following allogeneic transplantation [Abstract]. Blood, 98(11), 190a.
  148. Hosing C, de Lima M, Phan M, Martin T, Giralt S, Couriel DR, Hicks K, Ippoliti C, Donato M, Komanduri K, Champlin RE (). Hemorrhagic Cystitis after Mismatched Unrelated Cord Blood Transplantation for Adults [Abstract]. Blood, 98(11), 383b.
  149. Gajewski J, Khouri I, Champlin RE, Saliba R, McMannis JD, Donato M, Ueno N, Couriel DR, Bibawi S, Shahjahan M, Ma Y, Giralt S (). Anti-thymocyte globulin (ATG) reduces risk of primary graft failure and many reduce acute graft versus host disease (aGvHD) in 212 non-myeloablative blood and marrow transplant (BMT) patients (pts) receiving unrelated or 1 antigen (Ag) mismatched (MM) related donor grafts [Abstract]. Blood, 98(11), 383b.
  150. de Lima M, Komanduri K, St John L, Wieder E, Lee M, McMannis J, Karandish S, Giralt S, Beran M, Couriel DR, Korbling M, Martin T, Andersson B, Bibawi S, Westmoreland M, Hosing C, Champlin RE (). Using two mismatched unrelated donor cord blood units for transplantation: analysis of chimerism and immune reconstitution [Abstract]. Blood, 98(11), 382b, 5308.
  151. Hartzog MG, Sadeghi TK, Couriel DR, Esfandiary N, Giralt SA, Khouri IF, Gajewski JL, Champlin RE, Andersson BS (). Hematopoietic stem cell transplantation (HSCT) for CML after IV busulfan/cyclophosphamide (IV BU/CY) vs thiotepa cytosan total body irradiation (TT-CY-TBI) [Abstract]. Proceedings American Association of Cancer Research 2900, 539.
  152. Khouri IF, Saliba R, Lee MS, Giralt S, Younes A, Couriel DR, Fayad L, de Lima M, Hagemeister FB, Housing C, McLaughlin P, Ueno N, Rodriguez MA, Korbling M, Gajewski J, Cabanillas F, Champlin RE (). Nonablative allogeneic stem cell transplantation (AST) for Non-Hodgkin’s lymphoma (NHL): improved outcome with low incidence of acute GvHD and treatment related mortality [Abstract]. Blood, 98, 1746a.
  153. Khouri IF, Saliba RM, Giralt S, Okoroji GJ, Younes A, Fayad L, Korbling M, Rodriguez MA, Couriel DR, Bibawi S, Hosing C, McMannis J, Cabanillas F, Champlin RE (). Long-term remission and low mortality Cisplatin, Fludarabine, Cytarabine nonablative preparative regimen and allogeneic stem transplantation (AST) for histologically aggressive Non-Hodgkin’s Lymphoma [Abstract]. Blood, 98(11), 190a.
  154. Couriel DR, Saliba R, Cohen A, Rondon G, Horton E, de Lima M, Martin T, Ippoliti C, Khouri IF, Gajewski JL, Giralt S, Champlin RE (). Selection of patients for antihymocyte globulin (ATG) treatment in steroid refractory acute (GVHD (SR aGVHD): Favorable response in isolated skin or GI involvement [Abstract]. Blood, 98(11), 355b.
  155. Couriel DR, Khouri IF, Andersson BS, Cohen A, Saliba R, de Lima M, Martin T, Giralt S, Champlin RE (). Graft-versus-host-disease (GvHD) after non-myeloablative (NMA) versus myeloablative (MA) conditioning regiments in fully matched sibling donor hematopoietic stem cell transplants (HSCT): An Update [Abstract]. Blood, 98(11), 404a.
  156. de Lima M, Shahjahan M, Madden T, Tran HT, Gajewski JL, Couriel DR, Giralt S, Donato ML, Anderlini P, Krbling M, Khouri I, Russell JA, Champlin RE, Andersson BS (). Fludarabine (Flu) and IV Busulfan (BU)± ATG: Low toxicity conditioning regimen for stem cell transplantation (SCT) in AML and MDA – Preliminary Results [Abstract]. Blood, 98(11), 345b.
  157. Couriel DR, Hartzog MG, Sadeghi TH, Esfandiary N, Cohen AI, de Lima M, Giralt SA, Gajewski JL, Champlin RE, Andersson BS (). Conditioning regimen and graft-versus-host disease (GvHD) after hematopoietic stem cell transplantation (HSCT): Intravenous Busulfan/Cyclophosphamide (BU/CY) vs total body irradiation (TBI) [Abstract]. Bone Marrow Transplant, 7, 69.
  158. Andersson BS, Thall PF, Madden T, Couriel DR, Wang X, Tran HT, Anderlini P, de Lima M, Gajewski J, Champlin RE (). Busulfan systemic exposure after the IVBuCy2 regimen correlates with acute Graft versus Host Disease and toxicity after Stem Cell Transplantation for CML [Abstract]. Bone Marrow Transplantation, 27, S185.
  159. Colares M, de Lima M, Yazji S, Khouri I, Anderlini P, Donato M, Couriel DR, Giralt S, Martin T, Hosing C, Krbling M, Champlin R (). Outcome of autologous hematopoietic stem cell transplant (auto HSCT) for patients (pts) with non-Hodgkin’s lymphoma (NHL) that fail to mobilize autologous peripheral blood stem cells (PBSC) [Abstract]. Blood, 96(11), 795a.
  160. Andersson B, Tran Hai T, Madden T, Esfandiary N, Gajewski J, Couriel DR, Giralt S, Donato M, Anderlini P, Krbling M, Khouri I, Kantarjian H, Champlin R (). Acute graft vs. host disease (aGvHD) and toxicity correlate with busulfan systemic exposure (Bu-SE) after the IV BuCy2 regimen and stem cell transplants (HSCT) for CML [Abstract]. Blood, 96(11), 393a.
  161. Couriel DR, Giralt S, de Lima M, Esfandiary N, Martin T, Donato M, Hicks K, Andersson B, Champlin R (). Graft vs host disease (GVHD) after non-myeloablative (NMA) versus myeloablative (MA) conditioning regimens in fully matched sibling donor hematopoietic stem cell transplants (HSCT) [Abstract]. Blood, 96(11), 408a.
  162. Couriel DR, Hicks K, Ippoliti C, de Lima M, Donato M, Martin T, Anderlini P, Khouri I, Andersson B, Giralt S, Champlin R (). Infliximab for the treatment of graft-versus-host disease in allogeneic transplant recipients: An Update [Abstract]. Blood, 96(11), 400a.
  163. Couriel DR, Hicks K, Ippoliti C, Donato ML, Martin T, Anderlini P, Khouri I, Andersson B, Giralt S, Champlin RE (). Infliximab for the Treatment of Graft-Versus-Host Disease in Allogeneic Transplant Recipients [Abstract]. J Clin Oncol, 1952a.
  164. Barrett AJ, Mavroudis D, Molldrem J, Couriel DR, Young NS (). Immune Modulation to Treat Leukemic Relapse Following Allogeneic Bone Marrow Transplantation: A Risk-Based Sequential Approach [Abstract]. Blood, 88(10), 1026s.
  165. Barrett AJ, Couriel DR, Dunbar C, Fox M, Young NS, OKunnief P (). Low Incidence of Acute GVHD Following Delayed T Cell Add-Back after T-Depleted BMT for Hematologic Malignancies [Abstract]. Blood, 86(10), 2463s.
  166. Mavroudis D, Jiang YZ, Hensel N, Couriel DR, Dermime S, Mahoney M, Barrett AJ (). Specific Depletion of Donor-vs-Recipient Alloreactivity to Prevent GVHD after Marrow Transplantation [Abstract]. Blood, 86(10), 2267s.
  167. Molldrem J, Dermime S, Parker K, Couriel DR, Hensel N, Jiang YZ, Mavroudis D, Mahoney M, Barrett AJ (). Cytotoxic T Cells Show Specificity to MHC Class I-Restricted Peptide Derived from Proteinase 3, A Leukemia-Associated Protein [Abstract]. Blood, 86(10), 1695s.
  168. Couriel DR, Mahoney M, Hensel N, Mavroudis D, Jiang YC, Dermime S, Molldrem J, Barrett AJ (). Donor-vs-Recipient Helper T Lymphocyte Precursor Numbers Given But Not Their Frequency Predicts GVHD in HLA Matched Sibling BMT [Abstract]. Blood, 86(10), 1575s.
  169. Couriel DR, Canosa J, Engler H, Molldrem J, Mavroudis D, Dun Dunbar C, Collins A, Wesley B, Barrett AJ (). Factors Predicting Outcome Following Reactivation of Cytomegalovirus After T-Depleted BMT for Hematologic Malignancies [Abstract]. Blood, 86(10), 853s.
  170. Dermime S, Molldrem J, Parker KC, Jiang YZ, Mavroudis D, Hensel N, Couriel DR, Mahoney M, Coligan JE, Barrett AJ (). Human CD8+ T Lymphocytes Recognize the Fusion Region of BCR/ABL Hybrid Protein Present in Chronic Myelogenous Leukemia [Abstract]. Blood, 86(10), 620s.
  171. Jiang YZ, Mavroudis DA, Dermime S, Hensel NF, Couriel DR, Molldrem J, Mahoney MH, Barrett AJ (). Exogenous Antigen Processing and Presentation with Induction of Cytotoxic CD4+ Lymphocytes by Chronic Myelogenous Leukemia Cells [Abstract]. Blood, 86(10), 618s.
  172. Cottler-Fox M, Couriel DR, Dunbar C, Carter C, Yu M, Barrett AJ (). Counterflow Centrifugal Elutriation (CCE) of Bone Marrow Reveals Two Patterns of Hematopoietic Progenitor Stem Cell (HPSC) Distribution in Normal Donors [Abstract]. Blood, 86(10), 474s.
  173. Barrett AJ, Dunbar C, Cottler-Fox M, Couriel DR (). T-Cell Depletion with Delayed Lymphocyte Add-Back to Reduce GVHD and Promote GVL in Patients Receiving HLA-Matched BMT for Leukemia and MDS [Abstract]. Bone Marrow Transplantation, 15(S2), 1995.
  174. Jiang YZ, Couriel DR, Malkovska V, Lewalle PA, Mavroudis DA, Hensel NF, Barrett AJ (). HLA-DR1 Transfected K562 Cells Inhibit NK Cell Cytotoxicity [Abstract]. Blood, 84(10), 289a.
  175. Mavroudis DA, Jiang YZ, Hensel, Couriel DR, Lewalle PA, Barrett AJ (). Selective T Cell Depletion to Prevent Graft Versus Host Disease (GVHD) in HLA Haplotype Mismatched Bone Marrow Transplantation (BMT) [Abstract]. Blood, 84(10), 737a.
  176. Couriel DR, Cottler-Fox M, Burt RK, Dunbar C, Hensel N, Young NS, Barrett AJ (). T-Cell-Depleted Marrow Transplants with Delayed Lymphocyte Add-Back to Prevent Relapse in Patients with Leukemia and MDS [Abstract]. Blood, 84(10), 334a.
  177. Pandite L, Couriel DR, Weinstein R (). Storage of Hematopoietic Stem Cells at -80 C DMSO-free Cryoprotectant [Abstract]. Transfusion, 33(9), 73s.

Video/Film/CD/Web/Podcast

  1. Couriel DR (). NOXAFIL®US Speaker-Training webcast session [Video]. Schering-Plough.
  2. Couriel DR (). Physician Educational Material, Videorecording: Clinical Aspects on the Treatment of Chronic GVHD with Extracorporeal Photopheresis [Video]. London, UK: Therakos, Inc..

Global Impact

Education History

Residency University of Buenos Aires
Internal Medicine
Resident
Professional Medical University of Buenos Aires School of Medicine
Medicine
M.D.

Long-Term Evaluation of the Biology and Outcomes of Hematopoietic Stem Cell Transplantation

Description: Not yet recruiting Keywords: Biorepository, Bone Marrow Transplant, Graft versus Host Disease, Stem Cell Transplant, Cord Blood Transplant Principal Investigator: Daniel Couriel

Huntsman Cancer Institute News

Huntsman Cancer Institute and Grand Valley Oncology Begin Telemedicine Clinic for Blood and Bone Marrow Transplant Patients

Huntsman Cancer Institute First Adult Cancer Hospital in Mountain West to Offer CAR T Cell Therapy to Patients

Photopheresis: Using Light to Alter the Immune System

Site Links

  • About Us
  • Academics & Research
  • Billing
  • Jobs
  • Giving
  • Maps & Directions
  • Newsroom
  • The Imagine Perfect Care Program

Helpful Links

  • Referring Providers
  • Find an Interpreter
  • Patient Rights & Responsibilities
  • Disclaimer
  • Privacy Statement
  • DNV GL Public Information Policy Statement
  • Non-Discrimination Policy
  • Webmaster

Contact Us

University of Utah Health

50 North Medical Drive
Salt Lake City, UT 84132

801-581-2121

  • Facebook
  • Twitter
  • Youtube

University of Utah

All clinical services and programs are part of University of Utah Health Hospitals and Clinics.

Copyright © 2018 University of Utah Health